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A B S T R A C T
The exploration of the validity of quantitative 2-deoxy-2-[fluorine-18]
fluoro-D-glucose (18F-FDG) Positron Emission Tomography/Computed
Tomography (PET/CT) to assess lung inflammation
Laurence Dominic Vass
Lung diseases are one of the leading causes of death in the UK; responsible for 20%
of all deaths each year. Inflammation is thought to be an important driver of the
pathogenesis and progression of several lung diseases. Positron emission tomogra-
phy/computed tomography (PET/CT) is an imaging modality capable of providing
functional and molecular imaging through detection of trace quantities of a radioac-
tive tracer. 18F-FDG is the most widely available tracer and in several small studies has
been used to investigate diffuse lung diseases such as chronic obstructive pulmonary
disease (COPD). These studies rely on quantification of the PET image.
Static acquisitions provide information on the biodistribution of the tracer at a sin-
gle time point after administration, the standardised uptake value (SUV) is the most
widely used measure of 18F-FDG uptake. Dynamic acquisitions provide information
on the spatial and temporal distribution of the tracer; linear and non-linear modelling
techniques allow estimation of the metabolic rate of 18F-FDG in the lung. Previous
studies have used a linear method called Patlak graphical analysis, whilst non-linear
compartmental models have been used more recently to estimate metabolism. How-
ever, these contending measures of pulmonary 18F-FDG uptake, which are putative
biomarkers of lung inflammation, have so far been disparately applied. Further, there
is nascent understanding that these imaging endpoints are affected by pulmonary air
and blood volume; the importance of this effect will likely depend on the disease and
its severity. These issues are exacerbated by the presence of respiratory motion and the
low signal- to-noise ratio achieved in PET studies. This has led to questions regarding
the utility of quantitative 18F-FDG PET to assess lung inflammation.
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In this work, prospective and retrospective clinical studies were used to assess the
clinical, biological and technical validity of 18F-FDG PET imaging endpoints in several
clinically relevant diseases. The central hypothesis was that pulmonary inflammation
can be assessed using quantitative 18F-FDG.
Using retrospective data from two complementary imaging studies, pulmonary 18F-
FDG uptake was investigated in COPD patients, ↵
1
ATD patients, smokers without
COPD and heathy non-smokers. The results demonstrate that the different 18F-FDG
imaging endpoints produce disparate findings, and this is exacerbated by the presence
of varying blood and air volumes due to emphysema. Nevertheless, measures derived
from Patlak analysis revealed elevated uptake consistent with the pathophysiologi-
cal understanding of the disease process and further demonstrated correlation with
other putative markers of inflammation hence, one could speculate that it relates to in-
flammation. Further, 18F-FDG imaging outcomes assessed using Patlak analysis were
shown to be more reliable than compartmental modelling outcomes. However, the
Patlak outcomes are composite measures, not only driven by inflammation but also
by pulmonary blood and air. In circumstances where differences in pulmonary blood
and air volume between subjects are substantial, it may not be a suitable biomarker
of inflammation, but it could be a useful marker of disease activity. Further tissue
validation and independent measures of pulmonary blood are required to support its
role as a marker of inflammation.
In a prospective study, dynamic 18F-FDG PET scans were used to evaluate pul-
monary inflammation in sarcoidosis patients and healthy controls. The results show
that 18F-FDG uptake was increased in sarcoidosis using Patlak analysis, whilst no
difference was found using SUV or compartmental models. Preliminary findings sug-
gest that the signal relates to inflammatory cell counts (macrophages and lymphocytes
were most numerous) rather than any one specific cell line; however, further evidence
is required to determine if 18F-FDG uptake is driven by underlying inflammation. Con-
sistent with previous findings, mismatch in CT and PET lung images has substantial
effect on the quantitative 18F-FDG outcomes; notably, Patlak outcomes were less influ-
vi
enced than compartmental modelling.
In summary, the observations made in this work demonstrate the substantial chal-
lenges of using 18F-FDG PET/CT to assess diffuse lung disease. Given the incongruity
between the different imaging outcomes, these data highlight that future studies
should be carefully planned with particular justification of the acquisition and analy-
sis methods. The results of this work suggest that Patlak measures may have the most
utility in diffuse lung disease. However, differences in Patlak measures should be in-
terpreted judiciously, as they may be driven by differences in pulmonary blood and air
along with inflammation; further study is required to determine if it may be a useful
marker of disease activity. In contrast, no differences in pulmonary 18F-FDG uptake
between patients and controls were found using compartmental modelling across all
studies. Equally, the SUV was found to have poor utility across studies. Future efforts
to expedite the use of novel tracers that are more specific to inflammation combined
with the development of improved noise reduction techniques may improve the utility
of quantitative PET/CT in the context of lung inflammation.
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µ Linear attenuation coefficient
AA Ascending aorta
AC Attenuation correction
ACE Angiotensin converting enzyme
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ALI Acute Lung Inflammation






COPD Chronic obstructive pulmonary disease
COR Coefficient of repeatability
COV Coefficient of variation
CT Computed tomography
DA Descending aorta
EANM European Association of Nuclear Medicine
EBC Exhaled breath condensates
EGF Epidermal growth factor
emeans Estimated marginal means
EVOLUTION An Evaluation Of Losmapimod in Patients With Chronic
Obstructive Pulmonary Disease (COPD) With Systemic In-
flammation Stratified Using Fibrinogen
EVOLVE Evaluation of arterial inflammation in obstructive sleep ap-
noea hypopnoea syndrome (OSAHs) and chronic obstruc-
tive pulmonary disease
EU European union




Forced expiratory volume in 1 second
FOV Field of view
FVC Forced vital capacity
GOLD Global initiative for chronic obstructive lung disease
GE General Electric
HRCT High resolution computed tomography
hsCRP High sensitivity C-reactive protein
HU Hounsfield unit
IDIF Image derived input function
IFN Interferon
IL Interleukine
ILD Interstitial lung diseases
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nsHV Never smokers (healthy volunteers)
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PDGF Platelet-derived growth factor
PET Positron emission tomography
PGA Patlak graphical analysis
PLE Panlobular emphysema
POB Plasma over blood
PSE Paraseptal emphysema
r Correlation coefficient
ROI Region of interest
SAD Small airways disease
SD Standard deviation
sHV Smokers (healthy volunteers)
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SPECT Single positron emission tomography
SUV Standardised uptake value
Sv Sievert
t Time
TAC Time activity curve
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UK United kingdom






Fractional blood volume (compartmental modelling)
V
ss
Steady state volume of distribution (patlak analysis)
VEGF Vascular endothelial growth factor
WCC White blood cell count
WBC White blood cell
WRSS Weights residual sum of squares
x
P U B L I C AT I O N S
L Vass et al. ’Advances in PET to assess pulmonary inflammation: A systematic re-
view.’ In: European Journal of Radiology 130 (2020), p. 109182. issn: 0720-048X. doi:
https://doi.org/10.1016/j.ejrad.2020.109182
http://www.sciencedirect.com/science/article/pii/S0720048X20303715.
L Vass et al. ’Reproducibility of compartmental modelling of 18F- FDG PET/CT to
evaluate lung inflammation.’ In: EJNMMI Physics 6.1 (2019), p. 26. issn: 2197-7364. doi:
10.1186/s40658-019-0265-8 https://doi.org/10.1186/s40658-019-0265-8.
D L Chen... L Vass et al. ’Consensus recommendations on the use of (18)F-FDG
PET/CT in lung disease.’ eng. In: Journal of nuclear medicine : official publication, So-
ciety of Nuclear Medicine (2020). issn: 1535-5667 (Electronic). doi: 10.2967/ jnumed.120.244780
D L Chen...L Vass et al. ’Quantification of Lung PET Images: Challenges and Oppor-
tunities.’ In: Journal of Nuclear Medicine 58.2 (2017), pp. 201-207. issn: 0161-5505. doi:
10.2967/jnumed.116.184796 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.
116.184796.
L Vass et al. ’Compartmental modelling of 18F- FDG to assess Pulmonary Inflamma-




A C K N O W L E D G M E N T S
There are many people I would like to thank, without whom, this work would not
have been possible.
Foremost, I am indebted to my supervisor Prof. Ian Wilkinson, his sage advice from
grant application through to publications, generous support and pithy observations
have been instrumental in driving me to complete this work. Equally, I am extremely
grateful to Fred Wilson, my industry supervisor, his insights, help navigating the lo-
gistical complexities, tremendous support, and fantastic sense of humour have helped
keep me on track throughout the project.
Special mention goes to Dr Joseph Cheriyan; his advice, guidance and countless
discussions with me, often at all hours, were invaluable. Also, for all our many discus-
sions regarding the technical details, I would like to thank Dr Sarah Lee, without her
helpful suggestions doubtless I would have been much more frustrated with MAT-
LAB. A big thanks to Dr Kasia Maki-petaja for all our informal chats, keeping me
laughing and making my time during the PhD the most enjoyable experience. Equally,
a special thanks to Dr Marie Fisk for all her insights and explanations about lung
diseases, for helping me regardless of how busy she was, and generally for being one
of the most agreeable people with which to work. I am also grateful to the count-
less times that Liz Husband and Beverley Reynolds helped me keep organised and
for knowing what I was looking for before I did, without them my studies would
not have run so smoothly, and they always made me smile. So many people from the
wider department deserve thanks: Dr Carmel McEniery, the nurses who were consum-
mate professionals, Dr Nick Bird and all the radiographers in PET/CT for helping the
imaging visits run smoothly and all those at the Papworth hospital particularly Dr
Muhunthan Thillai for his infectious enthusiasm.
Finally, to my family, for putting up with me working at unearthly hours and who
have been nothing but supportive over the last 4 years.
xiii

T H E S I S O V E RV I E W
Chapter 1 provides an overview of diffuse lung diseases and the role of inflammation.
More detailed information is provided on the two principal diseases under investi-
gation in this work: chronic obstructive pulmonary disease (COPD) and sarcoidosis.
Existing clinical measures of pulmonary disease and inflammation are introduced
with emphasis on their shortcomings and the need for new biomarkers of pulmonary
inflammation. A summary of the imaging methods used in diffuse lung diseases is
provided. Finally, I reproduce my recently published systematic review of PET imag-
ing of lung inflammation.
Chapter 2 details the mathematical and physics background required to understand
quantitative 18F-FDG PET. Each method used to estimate 18F-FDG uptake is described
with the mathematical derivations, where relevant. Importantly, it describes the in-
fluence of pulmonary blood and air on the 18F-FDG PET imaging endpoints. The
hypotheses and aims of this work are summarised at the end of the chapter.
Chapter 3 describes the methodology which is common throughout this work, in-
cluding clinical measurements, image acquisition, image analysis and statistics. It in-
cludes a description of the bespoke analysis pipeline that I developed to evaluate the
quantitative 18F-FDG imaging endpoints. Further, I performed all statistical compar-
isons, as described in this chapter, in all further chapters containing data. Methods
which only apply to a specific chapter are detailed in the relevant chapter.
Chapter 4 discusses the results of quantitative 18F-FDG PET lung imaging in a
large cohort of COPD subjects from two retrospective complementary imaging stud-
ies; which I analysed using the bespoke pipeline that I developed. Further, 18F-FDG
uptake is compared to ↵
1
ATD patients, current smokers without COPD and healthy
never smokers. The different quantitative 18F-FDG PET imaging outcomes are com-
pared and contrasted by evaluating their variability, repeatability, reproducibility and
xv
relationship to clinical measurements.
In chapter 5 I hypothesised that COPD subtypes defined by visual and quantitative
CT are associated with varying degrees of pulmonary inflammation as assessed by
18F-FDG PET. To accomplish this, I established a collaboration with lung specialists
including a thoracic radiologist from the Royal Brompton Hospital to categorise the
patients using their CT scans; I then reanalysed and interpreted the PET imaging end-
points in these groups. Further, the impact of different 18F-FDG PET outcomes are
investigated in a COPD sub-type with the confounding influence of emphysema min-
imised, and compared to smokers and never-smokers.
Chapter 6 describes a prospective study of sarcoidosis patients that I designed. I
was involved in all elements of this study including writing the grant application,
study design, protocol development, imaging manual and optimising the PET/CT ac-
quisition, completing the required IRAS and ARSAC documentation, completing case
report forms (CRFs), attending/arranging subject visits, image analysis and interpre-
tation. The pulmonary 18F-FDG signal in sarcoidosis patients is compared to healthy
controls; notably, this includes comparing 18F-FDG uptake derived from both static
and dynamic acquisitions, which has yet to be performed in pulmonary sarcoidosis.
Further, the biological validity of the imaging biomarkers of inflammation is assessed
by comparing these against clinical measures of inflammation obtained from inflam-
matory cell counts in bronchoalveolar lavage fluid (BALf) and plasma biomarkers of
inflammation. In addition, the technical validity of 18F-FDG imaging outcomes is ex-
plored by investigating the influence of respiratory motion on quantitative 18F-FDG in
sarcoidosis patients.
Finally, chapter 7 provides a discussion and my conclusions given the results of
the studies undertaken in this work. Speculations are made on the future directions
of PET/CT imaging of pulmonary inflammation and suggestions for future work are
given.
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B A C K G R O U N D
1.1 diffuse lung diseases
Respiratory disease represents a considerable burden to the healthcare system: chronic
obstructive pulmonary disease (COPD) alone is the third largest cause of mortality in
the UK and the percentage of deaths worldwide is predicted to rise from 6.6 to 8.6%
in the next decade [1]. The costs of healthcare and lost productivity due to COPD is
equally remarkable: in the EU it is estimated to be a staggering e48.4 billion. Asthma
- a condition which results in few deaths but causes significant morbidity within the
population - costs e33.9 billion according to the same research. The causes of many
respiratory diseases are often preventable: approximately half the economic burden is
attributable to smoking and poor air quality [1]. Despite considerable effort, treatment
options remain limited: the probability of a drug successfully entering the market for
lung indications has been estimated as 16%, the lowest of the major indications [2].
The reasons are multi-factorial and partly due to the lack of sensitive biomarkers
which accurately reflect underlying disease. Clinical manifestations and severity of
lung diseases vary widely, there is a need for biomarkers which identify phenotypes
that exhibit rapid progression or patients who respond more effectively to novel ther-
apies.
Sections 1.2.1 and 1.2.2 provide more in-depth discussion of the two principal dif-
fuse lung diseases investigated in this work: COPD and sarcoidosis.
1.2 the role of inflammation in diffuse lung disease
Persistent inflammation is thought to be the driving factor in many diseases [3]. In
the lung, inflammation is thought to be the underlying cause of several diseases; im-
1
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plicated in the pathogenesis, progression and severity. The pathophysiology of lung
inflammation can be broadly categorised into focal or diffuse with further refinement
into those affecting the airways or parenchyma [4].
Inflammation is a response to an invading pathogen or endogenous signals from
damaged cells; the consequences are tissue repair or pathology. Understanding the
inflammatory response is challenging owing to the complex interactions of molecu-
lar, immunological and physiological processes. In several diseases including cancer
and atherosclerosis, inflammation is now considered an important driver of the dis-
ease process [3]. The profile of the inflammatory response is dependent on the dis-
ease and the tissue involved. Indeed, within the spectrum of lung diseases the initia-
tion, sequence of events and resolution can vary widely. For example, asthmatic pa-
tients suffer from inflammation of the airways which develops from a predominantly
eosinophilic response after an allergic reaction to an inhaled substance [5]. However,
asthma is a heterogenous disease; in fact, it is considered an umbrella term covering
many endotypes and phenotypes [6], it is now realised that management must be in-
dividualised to the phenotypic characteristics of each patient [7].
One distinction that is often made is between acute and chronic pulmonary inflam-
mation. When the resolution of an acute response is incomplete, the lung exhibits a
chronic response which aims to clear the debris, prevent infections and repair lung
tissue. Table 1.1 is a summary of the immune mechanisms in common respiratory dis-
eases as outlined in [8]. The key components include macrophages, neutrophils and
lymphocytes; with cytokines dictating the extent and type of response. Typically, Th2
cytokines play a major role in chronic inflammation leading to fibrosis.
In summary, the immune response in respiratory disease involves a complex inter-
play of cells, cytokines and other mediators. Despite substantial efforts to unravel the
key inflammatory components involved in diffuse lung disease, the mechanisms by
which inflammation causes lung dysfunction remain uncertain and further work is
needed to understand the drivers of the disease progression. Measurements which
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Table 1.1: Overview of main components of inflammatory response in some common lung
diseases.
Disease Pathology Cells Mediators
COPD
Alveolar apoptosis Macrophage MMP12,8,9
poor phagoctosis of apoptotic neutrophils !
necrosis !" NE release
Neutrophil cathepsin; S,L,G,
NE, IFN- , MIG
# VEGF CD8+ T cell TGF- , EGF,






Airway inflammation, Fibrosis and SMC Eosinophil # IL-10









Epithelial!mesenchymal transition, injury! Fibroblast, IL-8, TNF-↵,








COPD = Chronic obstructive pulmonary disease, EGF = epidermal growth factor, IFN = interferon, IL = interleukine,
IPF = idiopathic pulmonary fibrosis, MIG = Monokine induced by gamma interferon, MMP = matrixmetalloproteinases,
NE = Neutrophil elastase, PDGF = platelet-derived growth factor,SMC = smooth muscle cell,
TGF = transforming growth factor, TNF = tumour necrosis factor, VEGF = vascular endothelial growth factor.
could complement the existing clinical measures of lung disease and are specific to
inflammatory processes are needed to help address these concerns.
1.2.1 Chronic Obstructive Pulmonary Disease
COPD is the leading cause of mortality in non-malignant respiratory diseases [9]; it is
an umbrella term which covers a complex set of conditions. COPD is characterised by
an abnormal inflammatory response which occurs as a result of inhaled stimuli. The
pattern of inflammation seen in COPD patients can vary dependent on the nature of
the stimulus. Nevertheless, there is a characteristic pattern with increased numbers
of neutrophils, macrophages, T and B Lymphocytes [10–12] (see figure 1.1 and table
1.1). Interestingly, this pattern is common in smokers without airflow limitation but
the response in COPD is amplified. The molecular mechanisms are still unknown,
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but if they could be understood might provide an explanation of which smokers go
on to develop airway obstruction. Patients exhibit progressive airflow limitation due
to remodelling of the small airways and destruction of lung parenchyma. Computed
tomography (CT) scans indicate that small-airway obstruction occurs prior to the de-
velopment of emphysema [13].
Figure 1.1: Pathophysiological mechanisms of COPD.
One of the ongoing challenges has been to define clinically meaningful phenotypes,
several suggestions have been made but these phenotypes have proved difficult to
identify in different populations with no link to any underlying mechanism. The lack
of progress with phenotypes of COPD restricts the ability to deliver specific therapies:
recognising that coexisting mechanisms may be interacting in complex ways paves the
way for identifying responder phenotypes [14].
COPD is also associated with systemic inflammation; the picture is far from clear
whether increased systemic inflammation is a consequence of lung inflammation or if
related to a co-morbid disease that affects the lung as well [15].
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Periods of acute increased inflammation occur during exacerbations, but the rela-
tionship with clinical outcomes and disease progression remains poorly understood
[16]. Clinical trials need to address the challenge that large numbers of patients need
to be studied over long follow-up periods. Biomarkers capable of assessing disease
activity (or surrogate markers) could help facilitate the development of efficacious
anti-inflammatory drugs. Indeed, if treatments are to become targeted to certain phe-
notypes then biomarkers that can target specific pathways might be needed.
1.2.2 Pulmonary Sarcoidosis
Sarcoidosis is a multi-organ granulomatous disease of unknown aetiology which most
commonly affects the lungs [17]. An antigen is phagocytosed primarily by macrophages
and through a complex series of interactions leads to the formation and accumulation
of granulomas. Eventually, the granulomas may mature and become encased in fibrob-
lasts and collagen leading to distortion of organ architecture and function. Although
in a proportion of patients the disease may resolve itself, others will go on to develop
progressive pulmonary fibrosis. There is a poor understanding of which patients will
require long term therapy and therapeutic options have not convincingly shown pre-
vention of progression or fibrosis [18, 19]. Patients often experience restrictive ven-
tilatory capability according to spirometry readings with reduced forced expiratory
volume in one second (FEV
1
) and forced vital capacity (FVC); in at least 50% of pa-
tients the ratio of FEV
1
to FVC is also reduced [19].
Sarcoidosis is diagnosed using compatible clinical and radiological features, radio-
graphic chest findings are often confirmed by tissue biopsy. Recently, endobronchial
ultrasound (EBUS) has gained in popularity, it allows clinicians to biopsy chest lymph
nodes to confirm the presence of granulomas with lower risk than the traditional trans-
bronchial biopsy. Sarcoidosis remains a disease of exclusion [17]; no single marker or
test has proven robust enough to provide a definitive diagnosis. Serum angio-tensin
converting enzyme (ACE) reflects the total granuloma burden in sarcoidosis [20]. How-
ever, there is some debate around its diagnostic and prognostic usefulness [21] .
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1.3 clinical markers of pulmonary inflammation
There are several measurements which are used in a clinical and research setting to
assess pulmonary disease, very few of these provide a direct measure of underlying
inflammation. Spirometry is the mainstay of evaluating disease severity in diffuse res-
piratory diseases. Although FEV
1
and FVC are not a direct measures of lung dysfunc-
tion nor direct indictors of inflammation, they are commonly used for diseases such
as COPD and they are widely used as the primary endpoints in clinical trials of respi-
ratory disease. However, spirometry has well recognised limitations [22]. Spirometry
is a global measurement therefore, may mask any regional changes in disease; further
it exhibits a long interval - typically, months to years - before a change in disease can
be identified.
Bronchoalveolar Lavage (BAL) fluid provides a picture of the cellular constituents
within the lung and has been used in an experimental model of lung inflammation to
correlate against imaging markers [23, 24]. This provides a picture of the intra-alveolar
cellular environment; differential cell counts are taken to reveal the make-up of the in-
flammatory response. However, it is an invasive procedure and therefore carries risk
of complications. Sputum collection allows quantitative assessment of the cells in the
upper respiratory tract. Sputum collection has a number of methodological challenges,
these have led to poor repeatability [25].
There is some evidence that circulating plasma levels of inflammatory cells may be
elevated in pulmonary disease; however, the origin of the increase is not well under-
stood. The relationship with pulmonary inflammation depends on the pathological
origins of the disease in question. In COPD, plasma fibrinogen, a soluble protein, has
been found to be elevated compared to healthy controls and further elevated levels
are associated with increased risk of exacerbation and death [26]. However, fibrino-
gen has also been used as a marker of cardiovascular disease (CVD) and this is a
comorbidity in COPD hence may not relate directly to lung disease, further there is
no direct evidence that there is a link between fibrinogen levels and pulmonary in-
flammation. Moreover, there is some controversy regarding the role of fibrinogen as
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a putative biomarker in other indications; studies indicate that it does not correlate
well with disease prognoses in coronary heart disease [27] or in lung cancer [28]. Sys-
temic markers may be complementary to the disease or represent a comorbidity; in
either case, parenchymal disease activity may be compartmentalised, therefore sys-
temic markers may not be truly reflective of lung inflammation.
There is considerable interest in whether chemicals in exhaled breath could be in-
dicative of disease, so called Exhaled Breath Condensates (EBC). In asthma, exhaled
nitric oxide (NO) has transitioned from research into clinical practice as a marker of
airways inflammation and helps to inform diagnosis [29]. However, it is still too early
to draw firm conclusions about EBC in inflammatory lung conditions and further
work will need to be performed to verify the relationship between EBC and inflamma-
tory burden.
1.4 imaging inflammation in diffuse lung diseases
Imaging has many benefits over other measures of pulmonary disease. Imaging can
provide whole lung measurements and regional information relating to disease; this
can be at the level of an individual image voxel or combined into any larger region
size (e.g. lobes). Imaging techniques are largely non-invasive and the images can be
analysed to generate biomarkers of disease; such putative imaging biomarkers could
be applied [30]
1. In early-phase clinical pharmacodynamic studies of anti-inflammatory therapies
2. As a complement to functional spirometry and other forms of imaging
3. As a tool to improve our understanding of the pathogenic mechanisms of these
complex lung diseases
Changes in the structure and function of the lung occur in an unpredictable manner
and reflect different stages of inflammation. Imaging techniques aid in the apprecia-
tion of such stages: CT can characterise the secondary pulmonary lobule and delineate
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morphology, to a lesser extent magnetic resonance imaging (MRI) is used to depict
morphology and provide additional functional information.
Nuclear medicine techniques encompass planar imaging, single photon emission com-
puted tomography (SPECT) and positron emission tomography (PET). The subsequent
sections focus on 3D imaging techniques (i.e. SPECT and PET) rather than planar im-
ages which are less quantitative. SPECT and PET are non-invasive functional imag-
ing modalities which enable quantification of underlying molecular and cellular pro-
cesses. They are designed to obtain an image of the biodistribution of radioactive
tracers (herein, called a tracer). In principle, any metabolic substrate, receptor, or drug
can be labelled for use as a tracer. Therefore, the potential to explore pathophysio-
logical processes is vast [31]. However, novel tracers are challenging to develop: a
time-consuming, multi-disciplinary process which often results in failure. Neverthe-
less, nuclear medicine imaging techniques are appealing as they have the potential
to demonstrate target engagement and in-vivo efficacy of a drug. Further, they can
interrogate mechanisms directly related to disease activity and so, be able to detect
changes at an earlier stage than CT alone. Since respiratory diseases exhibits distinct
differences in inflammatory cell involvement [8], an ideal tracer will be specific, la-
belling only the molecular target responsible for disease progression. SPECT imaging
suffers from poorer spatial resolution and is less quantitative than PET imaging, which
may explain the predominance of the latter in the context of lung inflammation. Given
that PET is the principal modality under investigation in this work, a detailed review is
devoted to the role of PET tracers in inflammatory lung disease, whereas an overview
is provided for the other modalities.
1.4.1 Computed Tomography
CT is the pre-eminent technique to characterise lung disease in the clinic, it provides a
detailed picture of lung anatomy based on the differential attenuation of x-rays by tis-
sue; radiographic contrast is high in the lung due to the large proportion of air. Despite
density changes caused by respiration, inflammatory processes are recognised by an
increase in density compared to normal tissue. Although the density changes are not
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specific for inflammation, their appearance and distribution are valuable to help with
differential diagnoses [32]. A review of the role of CT imaging in non-infectious in-
flammatory diseases categorises the conditions as airways, vascular or interstitial pre-
dominant [33]. Currently, high resolution CT (HRCT) is capable of delineating down
to the 8th generation of the airways and characteristic patterns are observable on
HRCT. For example, in airways disease: areas of debris, fluid, inflammatory cells and
bacterial pneumonia cause opacities and consolidation. In HRCT scans of interstitial
lung diseases (ILDs) progressive fibrosis leads to honeycombing whereas non-specific
pneumonias manifest as ground-glass opacities. In a study of smoking related inflam-
mation, it was found that cumulative and current smoking were associated with high
attenuating areas on CT due to inflammatory changes [34].
In summary, inflammation appears in predictable patterns on CT scans which are use-
ful to distinguish different causes of lung inflammation. Since CT cannot delineate
disease activity, quantification of inflammatory burden is limited especially in condi-
tions where inflammation is widespread.
1.4.2 Magnetic Resonance Imaging
Currently, MRI has a limited role in diffuse lung diseases; the low density of protons
and susceptibility artefacts at the air/lung interface result in a low signal-to-noise ratio.
Contrast-enhanced MRI using intravenous administration of paramagnetic contrast
agents or inhaled hyperpolarised gases has improved the situation [35]. Gadolinium
leads to enhancement of signal in tissues either through interstitial or intravascular
enhancement, in previous studies of ILDs, early enhanced lesions were indicative of
active disease [36] whereas fibrotic lesions were characterised by late enhancement
[37]. As a tool to investigate pulmonary ventilation and microstructure, the hyper-
polarised gases 3He and 129Xe have emerged as a promising technique in MRI. For
example,129Xe MRI has shown both structural and functional information on fibrotic
change and gas exchange in IPF [35]. However, a recent systematic review acknowl-
edged that there was only weak evidence for the use of MRI in the assessment of ILD
[38]. Although, MRI of the lung is challenging, the non-ionising radiation makes it
appealing in conditions which afflict younger patients. MRI may have a role in cystic
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fibrosis (CF) where unlike CT, it is capable of providing additional functional infor-
mation such as perfusion, pulmonary haemodynamics and ventilation. Nevertheless,
quantitative MRI is limited in this context due to the low SNR, non-linearity of contrast
media to MR signal and inhomogeneities due to the physical set-up [39]. In conditions
with loss of tissue due to parenchymal destruction and consequent restricted blood
flow, the corresponding loss in MR signal creates an even more challenging situation.
Similar to CT, the role of MR in such conditions may be limited to functional param-
eters and respiratory dynamics [40]. Although limited principally to morphological
changes and perfusion defects in ILD, there has been some evidence to indicate its
use for assessment of inflammation: only recently has it been possible to achieve suit-
able image quality with MRI in ILD, and this has allowed inflammatory lesions to
demonstrate a hyperintense MR signal [36]. Doubtless, further improvements in im-
age quality will continue to be made; motion correction and development of advanced
MR sequences will contribute to this end.
1.4.3 SPECT
There are a number of SPECT tracers which target inflammatory activity. 67Ga-Citrate
localises in inflammatory areas, it has been suggested that the tracer binds to neu-
trophils predominantly [41]. However, there are only very few studies that have in-
vestigated its use in diffuse lung diseases [41, 42] and none within the last decade
indicating that it has been supplanted by other techniques. 111In was used in an early
animal model of pulmonary inflammation, providing the first evidence of migration
of immune cells in inflammatory conditions [43] but several factors have limited its
further use in the lung including poor image quality.
In-vitro cell labelling has had some promising initial findings: a study of COPD pa-
tients demonstrated increased neutrophil accumulation and retention compared to
healthy controls using 99mTc labelled neutrophils [44]. The authors noted the criti-
cal importance of labelling technique to avoid the neutrophils become activated. In
asthma, a condition characterised by eosinophilic inflammation, labelling of eosinophils
with 99mTc revealed an increase in 24 hour accumulation compared to healthy con-
trols [45]. The findings are suggestive that eosinophil labelling could be an imaging
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biomarker for the disease, specifically for monitoring response to therapy. Although
cell labelling has much potential, its widespread use may be limited by the expertise
and facilities needed for the careful preparation of the labelled immune cell [44].
Matrix-metalloproteinases (MMPs) are a family of proteinases thought to play an
important role in the repair of alveoli. Investigation of the pathogenesis of COPD has
led many investigators to explore the role of MMPs [46]. Although still in the early
pre-clinical stages of development, ligands which target MMP activation using 99mTc
have been tested in a murine model [47]. The authors demonstrated a correlation be-
tween lung uptake of the tracer and CD68 expression, suggesting that MMP activation
reflects the macrophage content. This is consistent with previous findings investigat-
ing vascular inflammation [48, 49], but further studies are needed to validate this in
humans. Equally, there has also been a few studies of PET tracers targeting MMPs
albeit in pre-clinical models (discussed in section 1.4.4). Molecular imaging of MMPs
may serve as a valuable tool in a range of human diseases.
1.4.4 Positron Emission Tomography
In a recent review article, the literature was searched to identify the current status and
future direction of PET tracers to assess inflammatory lung disease [50]. The diseases
under investigation were heterogenous across studies therefore, the literature is sum-
marised below according to tracer ligand.
Fluorodeoxyglucose
18F-FDG is the most widely used tracer clinically. Whilst it is a non-specific indicator
of inflammation, activated immune cells are known to increase their glucose turnover.
Thus, investigators have reasoned that accumulation of 18F-FDG may be reflective of
increased inflammatory activity. Several other excellent reviews have highlighted the
role of 18F-FDG PET in the context of inflammatory lung diseases alongside other
imaging modalities and clinical biomarkers [22, 32, 51]. With a focus on quantitative
18F-FDG PET, a collaboration of specialists reviewed current approaches to evaluate
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pulmonary inflammation using 18F-FDG PET [30].
Human studies of lung diseases using 18F-FDG PET are summarised in [30]; its non-
specific nature has allowed it to be utilised in several lung diseases including Cystic
Fibrosis (CF), Acute Respiratory Distress Syndrome (ARDS), Acute Lung Inflamma-
tion (ALI), Interstitial Lung Diseases (ILDs), COPD and Asthma.
Several small studies have shown that pulmonary uptake of 18F-FDG is increased in
COPD, asthma and ILDs when compared to control subjects [52–62]. In COPD, 18F-
FDG uptake has been shown to correlate well with clinical markers of disease severity
[54] and is associated with disease progression [56]. In asthma, regional 18F-FDG up-
take may serve as a predictive biomarker and help distinguish phenotypes [58]. In
CF, it has been suggested that 18F-FDG uptake may help to identify more aggressive
phenotypes [63, 64]. Using an established model of acute inflammation in healthy
volunteers, several studies have highlighted that 18F-FDG uptake could serve as a
reliable method to evaluate response to anti-inflammatory drugs [23, 24, 65]. Taken
together, the data summarised in [30] are compelling and support the use of 18F-FDG
for monitoring inflammation and potentially for phenotyping patients. However, care-
ful thought needs to be given to the methodological differences in the analysis and the
origin of the 18F-FDG signal before firm conclusions can be drawn [66] (see chapter 2).
Further, clinical validation has yet to be performed.
Understanding the origin of increased 18F-FDG signal remains challenging: neu-
trophils, macrophages, lymphocytes, eosinophils and structural cells have all been im-
plicated in 18F-FDG scans of inflammatory processes [57–59]. Consequently, 18F-FDG
PET lung images probably reflect an integrated inflammatory response. Interpreta-
tion of 18F-FDG lung imaging is confounded by the substantial proportions of air and
blood in the lung; quantification is similarly affected with several correction strategies
reported in an attempt to more accurately assess the lung tissue signal (detailed discus-
sion in chapter 2). Although static measures are simpler to apply clinically, dynamic
acquisitions allow greater scope for robust correction of these confounding factors.
The proportions of air, blood and tissue will vary with disease and as a consequence
of disease progression. To improve reproducibility in 18F-FDG PET, standardisation
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of acquisition and analysis protocols are of paramount importance [30, 67]. To that
end, a wide-ranging group of experts recently provided recommendations on optimal
protocols [68]. Although this will no doubt improve reliability of imaging endpoints,
further studies providing technical and clinical validation of quantitative 18F-FDG PET
could foment more widespread confidence in the technique. Furthermore, the cohorts
studied so far have typically been small; larger studies will be required to help estab-
lish the clinical relevance of increased uptake of 18F-FDG PET in lung disease.
Due to its wide availability, 18F-FDG PET will likely remain the principal tracer for
investigation of lung diseases; despite its shortcomings, it has shown promise in iden-
tifying suspected inflammatory disease and correlates well with clinically relevant
markers of disease.
Nitrous Oxide Synthase (NOS)
Nitrous Oxide Synthase (NOS) comes in several forms; only inducible NOS (iNOS)
is excreted during the inflammatory response and repair process. iNOS is an impor-
tant substrate expressed in a variety of inflammatory diseases; thus, it represents a
desirable target for a PET label. A few pilot studies have investigated the feasibility
of 18F-NOS, an inhibitor of NOS which binds primarily to iNOS [69, 70]. Following
initial promising results in a murine endotoxin challenge model, the feasibility and
dosimetry of 18F-NOS was assessed in cardiac transplantation patients [70]. In the
first application of 18F-NOS in the lung, Huang et al [71] experimentally induced
lung inflammation in a cohort of healthy volunteers (n=7) using a well-established
endotoxin model [23]. Baseline scans were compared with scans post endotoxin chal-
lenge (taken approximately 12 hours post challenge). The PET signal was correlated
against immunohistochemical staining of BAL fluid cells and exhaled nitric oxide
measurements. A modest but statistically significant difference was detected in the
exposed lung between baseline and follow-up scan (distribution volume ratio (DVR):
0.42 ± 0.07 vs 0.54 ± 0.12; p < 0.05); the control lungs exhibited no difference. Un-
like 18F-FDG, 18F-NOS is a reversible tracer and therefore unable to take advantage
of localised tissue retention which may explain the low uptake compared to simi-
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lar protocols with 18F-FDG [23, 65]. Despite seemingly disappointing uptake, a lack
of change in exhaled nitric oxide measurement does indicate that 18F-NOS may be
sensitive enough to identify mild regional changes undetected by whole lung mea-
surements. The authors recognised that changes in radiochemistry may improve the
clinical applicability: specifically, the presence of metabolites and rapid clearance. Fur-
ther, it is reasonable to assume that the expression of iNOS may be greater in diseased
individuals than healthy controls which may improve the signal. Further human stud-
ies in relevant disease cohorts will be able to ascertain the clinical utility of 18F-NOS.
Investigators are further exploring 18F-NOS to provide an imaging endpoint in a trial
evaluating lung inflammation in e-cigarette users, cigarette smokers and healthy vol-
unteers (ClinicalTrials.gov reference: NCT03721822).
Animal Studies
The paucity of tracers used in human studies to assess lung inflammation is clear
from the preceding section. Indeed, the significant challenges in developing novel trac-
ers has led to few crossing the gap from animal to human studies. Hence, to present
a comprehensive picture of emerging PET tracers, the preclinical studies undertaken
to assess lung inflammation are summarised below.
Matrix Metallo-Proteinases (MMPs) inhibitors
As introduced earlier, MMPs likely play an important role in diseases such as COPD,
substrates which act as MMP inhibitors have been developed based on NFR recep-
tors [72]. The first reported PET tracer synthesised targeting MMPs was (R)-N1-((S)-
1-(((S)-1-amino-6-(4-([18F]fluorobenzamido)-1-oxohexan-2-yl)amino)-1-oxo-3-phenyl propan-
2-yl)-N4-hydroxy-2-isobutylsuccinamide (called [18F]-FB-ML5) [73]; it was administered
to mice after using cigarette smoke (CS) exposure to induce lung inflammation (n=6)
and compared to an unexposed control group (n=5). Despite a generally low uptake
in the lung, a two-fold increase was observed (90 minutes p.a.) in the CS exposed
group. However, in ex-vivo lung samples, no difference was observed between groups
- it is unclear if methodological issues confounded the result: a BAL procedure was
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performed immediately prior to the ex-vivo biodistribution study.
Observing the unfavourable target to background ratio of [18F]-FB-ML5, Kondo et
al undertook further development work for ligands targeting MMPs [74]. They evalu-
ated several target substrates and identified 18F-IPFP as a candidate with the highest
binding affinity for MMP-12 and MMP-5. Biodistribution data indicated a four-fold
increase in the lungs of CS exposed mice (n=18) compared to unexposed controls
(n=18). However, PET imaging data in the murine lungs were less encouraging: up-
take between exposed and control mice proved unremarkable; interestingly, the oppo-
site was observed with [18F]-FB-ML5. One explanation, posited by the authors, may
be due to the poor relative expression of MMPs in the CS exposed group compared
to control group. Accurate models of chronic lung disease such as COPD remain lim-
ited: previous work has shown CS induced models may not reflect the same pattern
of inflammatory response as in humans [75]. In future human studies, it would be rea-
sonable to expect increased MMP expression in COPD patients [76]. Further, it is not
clear why kinetic analyses were not attempted given that dynamic acquisitions were
undertaken, since this may have proven helpful to overcome the low target to back-
ground ratios [22]. Given the nascent understanding of the role of MMPs to the disease
process, PET tracers targeting MMPs could serve as a source of selective biomarkers
when evaluating synthetic inhibitors of MMPs.
Trans-locator protein (TSPO) receptor
Trans-locator protein (TSPO), originally known as peripheral benzodiazepine recep-
tor (PBR), is expressed on the mitochondrial outer membrane of several cells, notably
monocytes and neutrophils [42], and has been widely explored as a marker of neuroin-
flammation [77–82], several groups have synthesised PET ligands that target TSPO.
The first substrate to be explored to assess pulmonary inflammation was (R)-[1(2-
chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide] labelled with Carbon-
11 (herein, 11C(R)-PK11195). Hardwick et al [83] experimentally induced lung inflam-
mation in mice and compared 11C(R)-PK11195 uptake to controls. Although there was
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a statistically significant increase in lung signal between LPS treated (n =3) and control
mice (n =3), the signal in exposed lungs was small and highly variable. In hindsight,
this is perhaps not surprising, given the shortcomings of PK11195 in neuroinflammation-
including high nonspecific binding and low signal- which have been subsequently
highlighted [84]. Kumata et al [85] later developed a series of ligands intended to
improve on the limitations of 11C(R)-PK11195. The most promising was an oxopurine
analog, N-Ethyl-N-(4-pyridinylmethyl)-2-(-7-[11C]methyl-8-oxo-2-phenyl-7,8-dihydro-
9H-purin-9-yl)acetamide, the authors named 11C[3a]. To assess the feasibility of this
tracer, PET images of rats exposed to LPS (n =4) were compared to unexposed con-
trol rats (n=4). Imaging revealed a 2.5-fold increase in the exposed lung compared to
controls (at 30 minutes p.a.). Biodistribution studies confirmed the imaging findings,
with a 2.1-fold increase in lung uptake compared to controls. However, the presence
of a significant metabolite and the requirement for 11C limits places limitations on its
broader applicability.
Building on this and previous work [86–88], Hatori et al used the novel tracer N-
benzyl-N-methyl-2-[7,8-dihydro-7-(2-[18F]fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl]acetamide,
known as [18F]FEDAC, to quantify lung inflammation [89]. Further, they examined the
relationship of imaging data with TSPO expression and cells. Using the same model
of LPS exposed rats, they compared uptake against 11C(R)-PK11195 and controls (n=4
for each group). At 24 hours p.a, quantitative PET revealed a 50% increase in signal
using [18F]FEDAC compared to 11C(R)-PK11195 in LPS exposed lung. Pre-treatment
with unlabelled ("cold") PK11195 showed negligible uptake of [18F]FEDAC indicating
excellent in-vivo specific binding for TSPO, consistent with the ex-vivo measurements
of radioactivity performed post dissection. The contribution of the pulmonary blood
to the signal rather than lung tissue alone is unclear, methods capable of providing
an estimate of blood volume such as wet-to-dry ratios or further imaging methods
may be helpful in future studies [90, 91]. Nevertheless, 18F-FEDAC seems a promising
candidate for imaging inflammation: it has been suggested that it may have a role in
predicting therapeutic effect in rheumatoid arthritis [92] and monitoring hepatic fibro-
sis [93].
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Future studies should aim to provide validation in human subjects. In neuroinflam-
mation, promising tracers continue to be investigated and may provide further options
for future lung studies [94, 95]. Additionally, these prior studies have demonstrated
the importance of histological validation for TSPO ligands, including a genetic predis-
position for different affinity binding patterns across individuals [96]. When designing
future studies it may be necessary to incorporate genotyping to stratify subjects into
low, moderate and high affinity binders. The specificity for particular immune cells
still needs to be addressed; although macrophages and neutrophils have been shown
to express TSPO, many other cells including bronchial/bronchiole epithelium also ex-
press TSPO [97]. Lessons learned from 18F-FDG studies are helpful here: future human
studies should be designed to identify the cellular origins of any changes in signal.
N-formylpeptide receptor
Neutrophils are thought to be a key driver of the response of the immune system,
active in the early stages of the immune response; in-vivo detection of neutrophils
would allow early investigation of acute response. The antagonist, cinnamoyl-F-(D)L-
F-(D)L-F (cFLFLF), was identified early as a peptide probe which binds with high
affinity to the neutrophil N-formylpeptide receptor (FPR) [98]; improved radiochem-
istry was achieved with the compound cFLFLF-PEG-DOTA labelled with 64Cu [99].
Evaluation of this tracer in a murine model of bacterial inflammation (n=6) revealed a
5 fold increase in signal in infected lungs compared with control lungs (n=4)[100]. Im-
munohistochemical staining indicated that in the infected mice (42 hours p.a.), there
was a substantial neutrophilic burden with few macrophages; this contrasted dramat-
ically with the control lungs which exhibited only normal alveolar wall structure. The
tracer also has an affinity for macrophages, so has been investigated and compared
to 18F-FDG imaging in type 2 diabetic patients; demonstrating stronger PET signal in
the macrophage containing pancreatic islets [101]. Future studies would require more
desirable properties of the radioisotope however, DOTA can also chelate to more com-
mon radioisotopes such as 68Ga with improved availability and half-life.
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Chemokine receptors
Given the promising results with peptide receptors targets, coupled with the ev-
idence that these receptors are over expressed on inflammatory cells (particularly
neutrophils), other institutions have explored different peptide probes. Chemokine
receptor 2 (CCR2) is found on monocytes and macrophages amongst other cells [102,
103]; it is up-regulated in lung diseases such as Asthma and COPD [104, 105]. The
recent identification of a peptide inhibitor, called extracellular loop 1 inverso (ECL1i),
which binds to CCR2, led to the development of a tracer called 64Cu-DOTA-ECLi [106].
Subsequently, this was shown to have a high affinity for macrophages and monocytes
in a lung transplantation study [107]. Further investigation of the feasibility of this
tracer to detect lung inflammation was undertaken using human tissue and animal
models [108]. Using an established model of acute lung injury in mice, intratracheal
LPS was administered prior to PET imaging (n=7) and compared to a control group
of phosphate buffered saline (PBS) treated mice (n=5). 64Cu-DOTA-ECL1i uptake was
assessed using the percentage injected dose (ID) per gram of tissue and peaked at
24 hours p.a. The LPS group demonstrated an approximate four-fold increase in pul-
monary signal compared to the control group. This confirmed the findings of the
biodistribution study. Sensitivity of the tracer to LPS was assessed in three groups
receiving low (n=3), intermediate (n=7) or high doses (n=3) revealing that the tracer
could distinguish low from intermediate or high doses.
Specificity was evaluated using competitive blocking with "cold" ECL1i (n=4), CCR2-
deficient mice (n=3) and treatment naive wild-type mice (n=3). The lung signal was
at similarly low levels in these three groups (mean <0.63% ID); compared to the LPS
treated group (mean 4.43%ID per gram). However, in resected human lung tissue from
COPD patients, CCR2 immunostaining revealed a lack of specificity, with a wide range
of cells CCR2-positive. Although overall the percentage of CCR2 expression was in-
creased in the COPD group relative to the donor group, there was substantial overlap
between them. The well documented heterogeneity of the COPD population may pro-
vide an explanation for this finding [109]. Nevertheless, autoradiography of the tracer
in COPD tissue sections demonstrated increased binding in human tissue with high
1.4 imaging inflammation in diffuse lung diseases 19
numbers of CCR2 positive cells compared to those with low numbers. CCR2 based
imaging with DOTA-ECL1i appears promising; further expanded radiochemistry to
enable 18F labelling would make the ligand more desirable for clinical use. Human
studies are underway and will provide important information on the utility of this
tracer (ClinicalTrials.gov reference: NCT03492762 ).
Summary of PET tracers
PET tracers can be targeted to specific cells and pathways to provide accurate mea-
sures of disease activity. Thus, their use in appropriately-designed studies could im-
prove our understanding of the role of inflammation in lung diseases. Development of
novel anti-inflammatory drugs has been stifled by the lack of robust, sensitive clinical
measurements [22]; PET derived imaging biomarkers have the potential to facilitate
the development of targeted therapies.
Development of novel tracers is a highly challenging process [31], reflected by the
paucity of tracers which have translated from bench to human studies. Indeed, it is
probable that 18F-FDG will remain the most widely utilised tracer in inflammatory
lung diseases; the existing data is compelling and supports continued use of 18F-FDG
for monitoring inflammation in a variety of diseases. However, existing studies have
used disparate acquisition and analysis methods, and there remains several unan-
swered questions concerning the validity of the analysis methodology and clinical
relevance of the imaging endpoints [30, 66, 67].
Considerable work has gone into developing tracers targeting specific causes of in-
flammation; those summarised in this review demonstrate the breadth of potential
targets. Although the low signal-to-noise ratio is a challenge which impedes all PET
tracer development in the lung, several tracers have demonstrated the potential for
monitoring inflammation in experimental animal models. Whether these promising
results translate into human studies remains to be seen, but they are encouraging and
warrant further investigation, for example, studies using 64Cu-DOTA-ECLi and 18F-
NOS are currently underway in humans. The imaging endpoints and correlative data
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provided in the animal studies are disparate, efforts to exclude confounding factors
such as blood volume changes and in-vivo specificity would be helpful to improve
confidence. The majority of studies were small in scope which makes it difficult to
make any firm conclusions about the future clinical utility of these tracers; larger stud-
ies in disease cohorts are needed. In future human studies, correlation with clinical
measures of disease severity would also improve knowledge of the clinical utility of
PET derived biomarkers.
2
Q U A N T I TAT I V E P O S I T R O N E M I S S I O N T O M O G R A P H Y
2.1 introduction
The previous chapter discussed the clinical background of diffuse pulmonary diseases,
in this chapter the theory behind PET is provided; quantifying a PET image is a pow-
erful method to estimate biological and physiologic information.
2.1.1 Positron Emission
Unstable nuclei undergo radioactive decay in order to reduce their energy state to-
ward a more stable configuration, prior to decay the nucleus is called the parent, the
products of the decay are the daughter nuclei. If the nucleus has an excess of protons
then decay may occur by spontaneously emitting a positron. Seldom occurring in iso-
lation, positron emission from a radioisotope may be accompanied by other forms of
radioactive decay (e.g. gamma emission). An example of a radioactive decay scheme
is shown figure 2.1. In PET, the decay of the radioisotope should: (i) be to a stable
daughter where no further radioactive decay is expected, (ii) have a relatively short
half-life (iii) be via positron emission with a high probability.
Positrons are emitted with a range of energies, the maximum energy is characteristic
of the radioisotope. The distance the positron travels in a medium before annihilation
is determined by the medium’s density and the positron’s energy. The positron range
is increased when traversing a lower density medium and when it has a higher energy.
Both of these affect the spatial resolution achievable in a PET image. The emitted
positrons interact with matter principally through scattering collisions, it subsequently
loses energy until it eventually annihilates with an electron. Annihilation results in
the conversion of the electron-positron pair into two gamma photons emitted at 180°
to each other, the energy of each photon is 511keV - this is a common feature of all
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positron emission regardless of radioisotope. Detection of the resulting pair of gamma
photons is fundamental to the process of image formation.
The positron-emitting radioisotopes are labelled to biologically functional compounds;
this radiotracer is then administered to a patient. The radiotracer preferentially accu-
mulates in regions where the compound is metabolised. The time-varying distribution
of the radiotracer provides a non-invasive way of determining pathophysiologic and
biologic information.
Figure 2.1: Decay scheme for Fluorine-18.
The main mode of emission is positron decay ( +) with a branching probability of 96.86%. Decay may
also occur via electron capture (✏ ) with a probability of 3.14%. m = minute, MeV = mega-electron volt.
2.1.2 PET scanners and image formation
At the core of the PET scanner are a series of rings which contain scintillation detec-
tors coupled to photomultiplier tubes. The purpose of this arrangement is to detect as
many true coincidence events as possible i.e. co-linear photon pairs from the scanned
portion of the body. In human tissue, positrons annihilate within the body, a short dis-
tance from the radiotracer and a proportion of the resulting photon pairs are absorbed
in the detector rings. When the two photons are detected within a short coincidence
time window (typically 1-10 ns), the joint detection forms a parallelpiped region called
a tube of response. The true-coincidence rate is proportional to the total amount of ra-
diotracer in the tube of response, this fundamental tenet allows an accurate 3D image
of the distribution of the radiotracer. Even in well designed systems the resulting im-
ages are dominated by noise due to the paucity of true coincidence events detected.
The density of the detectors, count-rate capabilities, the duration of acquisition and
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the amount of injected radiation determine the noise level.
Modern PET scanners are usually combined with a complementary image modality
which can provide a more detailed picture of anatomy. A computed tomography scan-
ner is the most common modality to be combined with PET as PET/CT; an additional
benefit is access to an attenuation correction map provided by the CT image (dis-
cussed in section 2.1.3. More recently, technological advances have allowed magnetic
resonance scanners to be combined into PET/MR scanners; the MR scanner produces
excellent soft-tissue contrast and allows additional functional imaging. However, some
challenges remain such as obtaining an accurate attenuation map.
The main aim of PET image reconstruction is to achieve an accurate distribution
of the radiotracer, this relies on algorithms which are usually proprietary and vary
widely amongst scanner manufacturers. The resulting images exhibit different noise
and image characteristics, which will depend on various factors such as the choice of
filters or any a priori assumptions [110] . These algorithms may be analytical or itera-
tive, the main example of the former is filtered back projection (FBP). Iterative methods
have become widespread in clinical practice and can produce improved signal-to-noise
ratios compared to FBP. Accurate noise modelling in the reconstruction process is de-
sirable due to the dominant appearance of noise in PET; however, for frequently-used
iterative image reconstruction algorithms the noise distribution is seldom known. Fur-
ther work is needed to establish the optimal reconstruction algorithm for PET lung
images [68]. In addition, various corrections for physical effects are needed in order
to obtain an accurate image of radiotracer distribution.
2.1.3 Physical Effects and Corrections in PET
The relationship between the number of true-coincident events and radioactivity is
subject to corrections for several confounding physical effects. These include correc-
tions for attenuation, randoms, scatter, patients’ movements, geometric variations in
efficiency, detector dead-time and radioisotope decay. A full description of these ef-
fects is provided in [111]. These effects must be estimated prior to applying the correc-
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tion. Gamma photons are attenuated by tissue on route to the detectors; CT provides
an estimate of this attenuation based on the reduction of x-ray intensities through the
patient. Although the x-rays used in CT are of lower energy than the 511keV photons
in PET, a bi-linear transformation is commonly utilised to correct this discrepancy.
In the lung, respiratory motion results in inaccuracies in qualitative and quantitative
PET images. The duration of PET scans makes respiratory motion unavoidable, this
contrasts with CT scans which can be obtained in a single breath hold of a patient. The
major effects of respiration on PET images include blurring leading to shape distortion
and loss of signal. Further, CT is used to generate an attenuation correction (AC) map
which is applied to the PET scan, the mismatch between the CT-AC and PET images
leads to inaccuracies in quantitative PET due to this mismatch. A number of methods
have been suggested to minimise the mismatch [68]. One advantageous method uses
cine-CT to generate a time averaged CT-AC that more closely mimics the lung image
from the PET acquisition [112, 113]. In a previous study of IPF patients using cine-CT,
investigators found significant errors were introduced to quantitative PET as a result
of motion and density mismatch between CT and PET [114]. A further development of
this approach phase matches the CT and PET scans using respiratory gating; however,
this results in noisier PET images. Alternative approaches have been suggested which
minimise blurring and mismatch without the noise increase [115]. The disease under
investigation and its severity are likely to impact the extent of density changes in the
lung during respiration, and therefore, magnitude of error introduced in quantitative
PET. As mentioned previously (see chapter 1), interpretation of PET lung images is fur-
ther confounded by the large proportion of air and tracer concentration in pulmonary
blood (detailed discussion provided in section 2.2).
2.2 quantitative pet
With the appropriate corrections in place, quantitative studies of tracer uptake can
be performed. PET allows both relative (i.e. one tissue region compared to another)
and absolute quantification. Methods to quantify the tracer uptake vary in complexity
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from static measures taken at a single time point post-injection to mathematical mod-
elling of the tracer dynamics. In the following sections, the different methods which
can been applied in diffuse lung diseases are discussed; given that 18F-FDG is the
most commonly utilised tracer, I focus on techniques developed primarily for this ra-
diotracer.
A major challenge in quantifying 18F-FDG in the lung is the poor signal-to-noise ratio;
the low basal uptake of 18F-FDG is a consequence of the low density of lung tissue
(due to large proportions of air). Indeed, this is likely to be a challenge for all PET
tracers targeting lung parenchyma and airways. A PET image can be considered a
superposition of different layers of signal corresponding to tissues or cells within the
region of interest (ROI); untangling the contribution of individual layers provides an
accurate means to assess the target tissue. Indeed, interpretation of lung PET images
is confounded by pulmonary blood; which in the healthy lung is substantially larger
(typically 15-20%) than other organs, e.g. the brain (typically 5%). The ROI may be
defined anatomically, e.g.the entire lung or individual lobes, it may be selected to
encompass a relevant disease process or a voxel-by-voxel approach may be adopted.
2.2.1 Static measures
Perhaps the simplest method to obtain an estimate of the tracer concentration relies on
delineating a ROI at single time point typically. Clinical 18F-FDG PET imaging proto-
cols are designed to give a favourable tissue-to-background ratio and optimal patient
throughput [116]. Typically intervals of between 45-60 minutes between administra-
tion of the tracer and the start of the acquisition are used (although optimal protocols









) is the concentration of the tracer at time, t
o
, A is the administered
activity and W is the weight of the patient. Although often normalised by total body
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weight, recent evidence from oncology patients indicate that lean body mass may
be more reproducible [118]. Currently, there is no evidence to suggest this may be
appropriate in the lung. Static measures, such as the SUV, are likely to be heavily
influenced by pulmonary blood and air, this has led to the exploration of alternative
methods that account for these effects [114].
2.2.2 Dynamic measures
Dynamic scans involve continuous data acquisition from the time of injection until a
late time-point (typically 60-90 minutes for 18F-FDG). The acquisition is divided into
a series of time frames with varying duration; typically, initial frames have a short
duration (e.g. 10 seconds), these are followed by longer frames later in the scan (e.g.
10 minutes). This type of acquisition allows the estimation of physiologic or biologic
parameters. Although static measurements are simpler to obtain, dynamic measure-
ments may be more sensitive when overall tracer uptake is low [119].
2.2.2.1 Compartmental Models
Kinetic modelling has traditionally be regarded as the gold standard method of quan-
tification in PET studies; well established applications include estimation of cerebral
metabolic rate (CMR) and neurological receptor binding (a general framework for
kinetic modelling is described in [120]). In compartmental models, the tracer is ex-
changed between a series of compartments; the rate of exchange is governed by the
rate constants. The concentration of the tracer within a compartment at a specified
time can be found by solving ordinary differential equations. Modelling the time vary-
ing distribution of the tracer using a series of compartments allows one to isolate the
signal of interest. Typically the models comprise one, two or three compartments de-
pending on the pharmocokinetics of the tracer and the disease. Such a model requires
an input function; the concentration of the tracer as a function of time in the blood or
plasma of an artery usually serves this purpose. These models are necessarily simplifi-
cations of complex biologic and physiologic processes with assumptions that must be
satisfied. The accuracy of these models needs to be assessed and periodically revisited
to ensure the conditions of the model are still met.
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2.2.2.2 18F-FDG Compartmental Model of Lung Inflammation
In the lung, provided there is not significant oedema, the two-compartment irre-
versible model [121] has been widely adopted to model the kinetics of 18F-FDG in
pulmonary inflammation [122] (see Figure 2.2).












































are the microparameters of the model [120]. The concentration of radioactivity in air,
C
a
(t), is assumed negligible. V
a
can be estimated as described in section 2.2.2.4.












Figure 2.2: Irreversible two-compartmental model describing the kinetics of 18F-FDG used
to evaluate lung inflammation.
In the absence of significant oedema, the concentration of 18F-FDG in a ROI in the lung can be described
by three compartments [122]: a blood compartment C
b
(t), an extravascular pre-cursor pool C
1
(t) and
phosphorylated (’trapped’) 18F-FDG compartment C
2
(t). The relationships between the concentration
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The microparameters and V
b
are estimated by minimising the weighted residual









where N is the number of time frames of the dynamic scan, i is the frame number
and W
i
is the weighting factor for each frame, C
m
(i) is the estimated concentration of
18F-FDG fitted from the compartmental model in frame i (i.e. equation 2.2) and Y(i) is
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the measured concentration from the PET scanner.
As discussed in Chapter 1, additional compartments may provide a more accurate
picture of 18F-FDG kinetics when there is significant oedema [119].
2.2.2.3 Input Function
An essential requirement of this approach is an accurate input function (C
p
(t)) [123];
this can be obtained from discrete blood samples from a peripheral vein during the
PET scan. Alternatively, an input function can be measured from the dynamic PET
images by delineating a ROI within a vessel in the field of view, referred to as an Im-
age Derived Input Function (IDIF). Optimal positioning of the blood vessel ROI has
been discussed extensively in application to 18F-FDG tumour kinetics [124] and car-
diac metabolism [125]; IDIFs derived from several different vessels were found to be
comparable to arterial samples. In pulmonary 18F-FDG kinetics, several regions have
been explored including the ascending & descending pulmonary aorta, left & right
ventricles, vena cava and aorta [126, 127]. The TAC extracted from the blood pool ROI
is then modelled as a continuous curve to reduce noise: models based on an initial
linear rise followed by a sum of exponentials have been proposed in tumour kinetics
[128], followed by correction to a plasma input function. In the brain, extensive effort
has been made to improve input function modelling including those based on refer-
ence regions [129] and methods using carotid or other blood vessels with one or more
manual samples [130–132] with voxel based approaches also feasible [133]. In the lung,
there remains a need for optimisation of input function modelling.
Early studies of kinetic models of cerebral blood flow (CBF) demonstrated the im-
portance of correcting the input function for time delay [134] (i.e. the time taken for
the tracer to travel between the sampling site and the tissue of interest). Methods to
estimate the delay between blood sample point and the tissue ROI are largely based
on these earlier observations in neurological PET [135, 136]. More recently, inaccura-
cies in time delay were shown to cause significant deviations in the microparameters
of a CMR kinetic model in rodents [137]. This applies equally to pulmonary compart-
mental models of 18F-FDG: incorporating a regional lung time delay has been shown
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to improve the fit to the experimental data compared to no delay in acute lung injury
(ALI) [138]. Further corrections such as accounting for the partial volume effect (PVE)
and spill-over in pulmonary 18F-FDG scans may be important [127] but the impact
of this approach on kinetic parameter estimation in humans has yet to be explored.
Dispersion of a tracer alters the shape of the input function, parameters estimated
from compartmental modelling are affected by dispersion but there is evidence that
graphical analyses (such as Patlak) are largely insensitive to dispersion [139].
2.2.2.4 Fractional Air Volume
In order to solve equation 2.2, an estimate of the fractional air volume, V
a
, in the ROI
needs to be obtained. Fortunately, CT has been shown to give an accurate measure of






















are the Hounsfield units for the lung, air and soft
tissue respectively. This methodology was originally devised to attempt to correct SUV
in the lung for the air fraction [53].
2.2.3 Graphical Methods
Compartmental modelling with PET data is non-trivial and is sensitive to noise par-
ticularly in the initial frames; alternative methods can overcome these issues. Patlak
graphical analysis (PGA) is a widely adopted technique applicable when irreversible
tracers are used. The seminal paper developing the mathematics was produced by Pat-
lak and the technique bears his name [141]. PGA is derived from a general compart-
mental model which makes no assumptions regarding the number of compartments
through which the tracer can be exchanged. Although originally intended for neuro-
logical studies [141], it has been applied in diffuse pulmonary diseases (see chapter 1).
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Applying PGA to the compartmental model of pulmonary inflammation (figure 2.2),
























































































































































































(t) is the concentration of the tracer in the lung ROI, C
p
(t) is the plasma
input function and Vc
ss
is the steady state volume of distribution of the tracer. Mea-
surement of C
p
(t) is described in section 2.2.2.3; note that it is derived from a blood
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(t) (the implications of this correc-
tion are discussed in chapter 4, see limitations in section 4.6). Equation 2.16 is that of
a straight line with a slope of K
ip
and an intercept equal to V
ss
. Comparing equations




















































are influenced by the blood and air contributions. The benefits of
PGA lie in its relative simplicity compared to compartmental modelling and its ability
to cope with noise (due to its regression over many time points). The rationale for
normalising the metabolic rate defined by equation 2.19 has been questioned previ-
ously [23]. Nevertheless, PGA may provide a composite measure of disease activity
and correlates well with measures of disease severity [54]; indeed, it continues to be
reported as a surrogate measure of pulmonary inflammation in humans [24].
2.3 summary of quantitative pet
The complex architecture of the lung and the small proportion of tissue - even in
healthy lung - compounded with the substantial tidal motion make quantifying ra-
diotracer concentration in diffuse lung diseases challenging. Currently, a great deal of
effort has been spent investigating and refining quantitative 18F-FDG as a marker of
2.3 summary of quantitative pet 33
Figure 2.3: Patlak graphical plot derived from an 18F-FDG PET scan.
This data was taken from a ROI around the whole lung of a COPD patient scan.
COPD = chronic obstructive pulmonary disease, ROI = Region of Interest
pulmonary inflammation. Despite this, no consensus on the most appropriate method
has been reached with static and dynamic approaches still routinely applied. Quanti-




vary significantly with disease and severity, which could lead
to different conclusions depending on the analysis method [66].
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2.4 hypotheses and aims
In this project, the principal hypothesis was that quantitative 18F-FDG PET/CT can be
used to assess pulmonary inflammation in diffuse lung diseases. In order to test this
hypothesis, prospective and retrospective clinical studies were used to assess the clin-
ical, biological and technical validity of 18F-FDG PET imaging endpoints. These were
performed in clinically relevant diseases including COPD, ↵
1
ATD associated COPD,
sarcoidosis and compared to positive and negative controls.
Hypothesis 1 (Chapter 4): COPD patients, ↵
1
ATD patients and smokers will have
elevated pulmonary inflammation as measured by 18F-FDG PET.
The aims of the studies described in Chapter 4 include:
1. To compare regional and whole lung inflammation in COPD participants, ↵
1
ATD
participants, current smokers without COPD and healthy never smokers using
quantitative 18F-FDG PET.
2. To compare and contrast the different quantitative 18F-FDG PET imaging out-
comes, evaluating their variability, repeatability, reproducibility and relationship
to clinical measurements.
Hypothesis 2 (Chapter 5): COPD subtypes defined by visual and quantitative CT
will be associated with varying degrees of pulmonary inflammation as assessed by
18F-FDG PET.
The aims of the study described in Chapter 5 include:
1. To compare lung inflammation (using quantitative 18F-FDG PET) between ra-
diologic sub-types of COPD and to explore associations between emphysema
severity and disease activity using 18F-FDG PET.
2. To investigate whether differences in treatment response could be identified in
these subtypes of COPD using longitudinal 18F-FDG PET scans.
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3. To assess the different 18F-FDG PET outcomes in a single subtype defined by the
mildest disease- thus minimising the confounding influence of emphysema- and
compared to smokers and never-smokers.
Hypothesis 3 (Chapter 6): Sarcoidosis patients will have an increased pulmonary
18F-FDG PET signal compared to healthy controls; dynamic measures of 18F-FDG will
further improve the distinction between these groups.
The aims of the study described in Chapter 6 include:
1. To compare the pulmonary 18F-FDG signal in sarcoidosis patients to healthy
controls; this includes comparing both static and dynamic measures of uptake.
2. To assess biological validity by comparing these quantitative measures against
clinical measures of inflammation obtained from inflammatory cell counts in
bronchoalveolar lavage fluid (BALf) and plasma biomarkers of inflammation.
3. To explore the technical validity of 18F-FDG imaging outcomes by investigat-




M E T H O D S
This chapter describes the methodology which is common for the study protocols
and analysis methods used throughout this work. This includes a detailed description
of the clinical markers of pulmonary disease, PET/CT acquisition protocols, image
analysis methods and statistical tests used. Individual chapters describe additional
methods, which only pertain to the work undertaken in those chapters.
3.1 clinical markers
3.1.1 Blood Based Biomarkers
Venous blood samples were collected according to a standard operating protocol for
the studies: a 4.7ml serum gel tube for full lipid profile, renal function and high
sensitivity C reactive protein (hsCRP); fibrinogen was analysed via the Clauss method
using a 2.7ml sodium citrate sample tube; standard haematology was evaluated using
a 2ml EDTA sample tube. Samples were processed either at accredited departments
within NHS hospitals or The Doctors Laboratory (TDL, London).
3.1.2 Pulmonary Function Tests
Spirometry was performed using the CareFusion MicroLab Spirometry (San Diego,
USA) according to joint American Thoracic Society and European Respiratory guide-
lines [142] and the best-performed procedure out of at least three attempts was recorded.
In COPD patients alone, spirometry was performed after inhaled bronchodilator med-
ication. The forced expiratory volume in 1 second (FEV
1
) is the amount of air exhaled
in 1 second after maximum inspiration; forced vital capacity (FVC) is the total exhaled
volume after maximum inspiration. A value of FEV
1
/FVC < 0.7 indicates airflow ob-
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3.2 pet/ct acquisition protocol
Scans were performed at the PET/CT Unit of Addenbrookes Hospital, Cambridge us-
ing the GE 690 Lightspeed Discovery VCT scanner (Milwaukee, Wisconsin) or Invicro
ltd (formerly Imanova), London using the Siemens mCT Biograph (Munich, Germany).
The acquisition protocols were matched as closely as possible.
Subjects were required to fast for 6 hours prior to the scan and told to avoid strenu-
ous exercise in accordance with the standard guidance from the European Association
of Nuclear Medicine (EANM) for 18F-FDG oncology imaging [143]. A blood glucose
level of < 11mmol/g was required for the subject to proceed to the scanner. Posi-
tioning aids were used to ensure the subject was comfortable: knee wedges and arm
straps were used. All subjects underwent a topogram - a low dose, full body image -
to aid in the positioning of the FOV in other scans. Further CT scans were performed
as described in the relevant chapters.
3.2.1 PET
After CT scans were completed, the subject was positioned in the PET scanner. 18F-
FDG was administered into the antecubital vein followed by a flush of saline (10ml).
The dynamic acquisition was initiated immediately prior to the administration; data
were acquired in list mode for 60 minutes post-administration (p.a.). Framing sched-
ules were study specific and described in the relevant chapters. Images were recon-
structed using proprietary algorithms: either the discrete Fourier transform (DIFT;
Siemens) or 3D Fourier rebinning filter back projection (FORE-FBP; GE). The FORE-
FBP algorithm was used (rather than an iterative reconstruction algorithm) in the
prospective study (see Chapter 6, all scans acquired on the GE 690 PET/CT scanner).
The rationale behind this choice was: (1) to ensure consistency with the retrospective
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data (chapter 4) and (2) to mitigate other identified issues such as bias found in the
iterative ordered subset expectation maximisation (OSEM) reconstruction algorithm
[144]. All PET images were corrected using an attenuation map formed from the CT
scan.
Discrete venous blood samples were acquired during the scan from the contralat-
eral arm; these samples were used to provide a plasma to blood ratio. Samples were
spun in centrifuge at 3000 revolutions per minute (rpm) for 5 minutes; 0.5ml of plasma
and whole blood were pipetted into a vial. Samples were measured three times in a
gamma counter for 60 seconds; the average value was used in calculations.
All scans were reported by consultant radiologist or nuclear medicine physician
using a static scan reconstructed in the final 15 mins (45-60mins).
3.3 pet/ct image analysis
3.3.1 Overview of the analysis pipeline
The goal of analysing PET/CT lung scans was to estimate pulmonary 18F-FDG uptake.
In this work several outcomes were used to estimate 18F-FDG uptake and these were





tained from Patlak graphical analyses and finally K
im
obtained from compartmental
modelling. The SUV is obtained from static acquisitions whereas the other outcomes
incorporate information on the time course of the tracer from the dynamic acquisition.
In order to estimate these outcomes, an analysis pipeline was developed; an overview
of the pipeline is shown in figure 3.1. This pipeline was implemented primarily in
MATLAB [145] (version R2016b). Below is a more detailed description of the stages
involved.
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Figure 3.1: Overview of the Analysis Pipeline for 18F-FDG PET/CT Lung Images.
A schematic overview of the different stages of the analysis pipeline and their relationships.
* CT refers to either standard resolution chest CT or cine-CT.
AC = attenuation correction, CT = computed tomography, PET = positron emission tomography, IDIF = image
derived input function, ROI = Region of Interest, TAC = time activity curve, µ = linear attenuation coefficient.
3.3.2 Image registration
The alignment of the PET and CT scans is inherent in hybrid scanners. Visual inspec-
tion of the registered PET and CT scans were made using viewing ITK-snap [146],
particular attention was paid to the heart and vessels as these are more readily ob-
servable than structures within the lung. Attempts were made to correct gross patient
movement using simple translation operations.
3.3.3 Lung and Vessel Segmentation
The purpose of segmentation was to extract a region of interest from an image (i.e. sec-
tions of lungs or vessels), the output of segmentation is a binary mask whose value is
1 in the ROI and 0 for all other points in the image. After a period of exploratory work,
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whole lung segmentations were undertaken using a semi-automated technique within
ITK-SNAP software [146]. The CT image is first pre-processed: a threshold based on
CT numbers of > -1022 and < 300 excludes soft tissue, blood vessels and bone from
the image leaving mainly lung airways and parenchyma. Next, an active contouring
method delineates the contours from a set of user defined seed points, major air ves-
sels were not included. The lung mask was manually inspected and corrected when
necessary.
Morphological operations were then performed: erosion with a disc shaped struc-
tural element with a radius of 3 pixels followed by an opening operation. The resulting
whole lung masks were then visually inspected: the first 5 minutes of the 18F-FDG PET
scan was summed and overlaid on the lung mask. Spillover of the 18F-FDG signal from
the heart and diaphragm were manually corrected, if required.
The lungs were further subdivided into twelve equal volume ROIs to investigate
regional difference in 18F-FDG uptake as has been performed in previous analysis
pipelines [66]. An example of these regions is shown in figure 3.2. These regions were
combined into larger volumes which more anatomical relevance: the upper, middle
and lower lung (by combining left and right, anterior and posterior segments).
The descending aorta (DA) was chosen as the vessel for the input function. The ra-
tionale for using the DA is based on previous work which revealed it to be preferable
in estimating kinetic rate constants [127]. A circular ROI was manually delineated and
positioned in the centre of the DA to minimise the partial volume effect, unless oth-
erwise stated a 5 pixel diameter was used. The ROIs were drawn over 25 axial slices;
the most superior slice was chosen in the aortic bifurcation. A summed 18F-FDG PET
image (0-5 minutes) was generated and used as guide to help with the placement of
the ROI and assess gross patient movement.
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Figure 3.2: Example of a regional lung segmentation for a subject.
Each lung was divided into 6 equal volume regions. These regions were combined to give larger lung
regions of interest.
3.3.4 Lung TACs and IDIF
For each subject, the binary mask obtained from the lung segmentations was applied
to the registered PET scan to obtain lung time activity curves (TACs). TACs represent
the concentration of 18F-FDG over time in the ROI. Blood TACs were obtained using
the vessel segmentation.
The blood TACs were first smoothed to minimise noise by fitting a function to the
data points. In general, the blood TAC was modelled by basis functions with a varying
number of exponentials with an initial linear slope as described in [147] ; the exponen-
tial model that best fits the blood TAC was found using a least squares algorithm.
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Next a correction was introduced for the time delay, ⌧, between the bolus injection
of the tracer and the arrival time in the lung ROI. Unless otherwise stated, to estimate
the time delay, a one-compartmental model was fitted to the first 5 minutes of the
smoothed blood TAC and lung TAC. Then a delay of ± 50 seconds in one second in-
crements was introduced and the delay was estimated by finding the minimum value
of the residual sum of squares on the model fit [66].
The clearance of a tracer is assumed from the plasma rather than blood in keep-
ing with previous studies and general kinetic modelling principles [66, 147] hence,
the blood TAC was converted into a plasma TAC using the plasma-over-blood (POB)
ratio. The POB ratio was calculated for each subject using the ratio of counts in the
plasma and blood from the discrete venous blood samples. The limitations of this cor-
rection are presented in detail in Chapter 4 (see Discussion).
3.3.5 Outcome Measures
For each subject, whole or regional 18F-FDG uptake in the lung was estimated using
the lung TAC and IDIF. An overview of the process to estimate the outcomes is shown
in figure 3.3. The SUV was calculated using equation 2.1 as the mean value in the ROI
(unless otherwise stated) where, C(t) was the average decay corrected concentration
from the final 30 minutes of the PET scan.
Patlak graphical analysis was used to estimate the rate of uptake of 18F-FDG in
the lung, K
ip
, and the steady state volume of distribution, V
ss





(t) were obtained from the lung TAC and the IDIF, using time points
t > 10mins. Further, the normalised uptake, nK
i
, described by equation 2.19 was also
calculated.
Compartmental modelling was used to estimate the metabolic rate constant (K
im
).
The Sokoloff irreversible two-compartment model was used to describe the kinetics
of 18F-FDG in the lung [121]. The fractional blood volume, V
b
, is a parameter that is
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Figure 3.3: Overview of analysis steps to estimate pulmonary 18F-FDG outcomes.









). The SUV is calculated using the average of the final time points of the lung
TAC.
CT = computed tomography, PET = positron emission tomography, IDIF = image derived input function,SUV =
standardised uptake value, TAC = time activity curve, Va = fractional air volume), Vb = fractional blood volume),
WL = whole lung
estimated in this model and is also reported as an outcome measure along with K
im
.
These outcomes were obtained by solving equation 2.2.




, a number of
inputs are required. C
p
(t) was defined by the IDIF and the measured concentration
of 18F-FDG in the lung was given by the lung TAC (i.e. Y
i
in equation 2.9). V
a
was
estimated using the CT-AC and equation 2.10.
The WRSS (equation 2.9) was minimised using the simulated annealing global op-
timisation method; this was implemented in a bespoke automated pipeline using the
MATLAB optimisation toolbox (version 7.5). A start point is required by the optimi-









multiple start points were used and obtained using the MultiStart function within the
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toolbox. The weighting factors, W
i

















Statistics were analysed using R version 3.0.0 with R studio version 0.98.953 [148].
Medians, means, inter-quartile ranges and correlations were used. When longitudinal
study measures were compared, changes from baseline were analysed using linear
regression model covariates included systemic markers of inflammation (e.g. WBCs,
Fibrinogen, hsCRP).
P-values < 0.05 were considered significant for all statistical analyses, except when
the Bonferroni correction was applied. All data are presented as mean ± standard
deviation (SD), percentages, or with 95% confidence intervals.
Bland-Altman plots were used to compare the different outcome variables as a mea-
sure of repeatability and reproducibility. The Bland-Altman coefficient of repeatability
is given by 2⇥ SD; we expect 95% of the difference to be less than this value. We also
reported the coefficient of variation (COV) as a further measure of repeatability.
Histogram plots were used to assess whether a normal distribution was observed in
a variable. To investigate group differences the Hedge’s g effect was used, as a further
complementary measure to the unpaired t-test .
Additional study specific statistical tests are discussed in the relevant chapters.
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1 8 F - F D G P E T / C T I N C H R O N I C O B S T R U C T I V E P U L M O N A RY
D I S E A S E
4.1 background
Chronic obstructive pulmonary disease (COPD) is a complex condition characterised
by a range of pathological changes including bronchitis and emphysema. Although
the molecular origins of the disease have yet to be fully elucidated, it is postulated
that inhalation of tobacco smoke (or other toxic air particulates) can trigger an ab-
normal exuberant inflammatory response which may persist even when the trigger
is removed. Inflammation is a driver of disease progression and is characterised by
increased lymphocytes, macrophages and neutrophils in the lung [11, 149–151]. For
COPD patients, current treatment options remain limited, leading to many remain-
ing symptomatic and experiencing moderate to severe exacerbations, despite being
on optimal therapy [149]. Development of alternative therapies has been unduly slow
and can be explained, in part, by the lack of biomarkers reflective of disease pheno-
types, progression or severity. Whilst Forced Expiratory Volume in 1 second (FEV
1
),
assessed by spirometry, is used to diagnose COPD, this measure does not relate well
to systemic inflammation or indeed to the impact of the condition on symptoms [152].
Doubtless, the difficulty of establishing clinically relevant phenotypes and endotypes
in COPD has contributed to the challenge of finding efficacious treatments.
Since glucose utilisation is increased in inflammatory cells, COPD patients should
exhibit increased pulmonary uptake of 18F-FDG, despite emphysematous loss of lung
tissue [153]. To date, only a handful of studies have used 18F-FDG in COPD patients:
a small study found whole lung uptake of 18F-FDG could distinguish COPD partic-
ipants from healthy controls and asthmatics [55]. In later work, the rate of 18F-FDG






f-fdg pet/ct in chronic obstructive pulmonary disease
Regional analyses of the lung also revealed that 18F-FDG uptake had a heterogenous
distribution which may be related to the emphysematous burden. One of the most
widely reported 18F-FDG PET imaging outcomes, taken as a surrogate of lung inflam-
mation, is the normalised rate of uptake, nK
i
, derived from Patlak graphical analysis
(PGA) [43]. However, alternative methods have been used to quantify pulmonary 18F-
FDG uptake, with the lung signal in each influenced to varying degrees by blood and
air content. Indeed, preliminary findings suggests that an extemporaneous choice of
18F-FDG PET imaging endpoint could lead to different conclusions [66]. To ensure
confidence in 18F-FDG PET as a research tool which could advance pathophysiologi-
cal understanding and therapeutics development in COPD, further work is urgently
needed to understand the limitations of these quantitative 18F-FDG outcomes.
In this chapter, 18F-FDG PET/CT scans from two parallel imaging studies are used
to compare and contrast the utility of quantitative 18F-FDG PET/CT imaging end-
points in a substantially larger dataset of COPD subjects (n = 85) than previously
reported. The clinical relevance of 18F-FDG uptake was investigated in relation to
validated markers of systemic inflammation and disease severity. Further, imaging
outcomes were compared in cohorts of ↵
1
ATD patients, healthy smokers (sHV) and
healthy non-smokers (nsHV). Finally, the technical validity was assessed by measuring




ATD patients and current smokers will have elevated pulmonary
inflammation as measured by 18F-FDG PET compared to never-smokers.
4.3 aims
The primary aim was to compare regional and whole lung inflammation in COPD par-
ticipants, ↵
1
ATD patients, current smokers without COPD and healthy never smok-
ers using quantitative 18F-FDG PET. The different methods were compared and con-
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All subjects provided written informed consent in keeping with the Declaration of
Helsinki. Subject data analysed in this work arise from two parallel imaging studies:
the EVOLUTION clinical trial and an observational study (EVOLVE) (REC 13/EE/0165,
UK CRN ID 1513).
EVOLUTION was a double-blinded, placebo controlled, randomised control trial
investigating a novel, unlicensed compound in Phase II drug development, Losmapi-
mod (a p38 MAPK inhibitor), in COPD participants [154]- the primary outcome of this
study was the assessment of vascular inflammation, which is reported together with
methodology elsewhere [155]. A favourable ethics opinion was granted from Cam-
bridgeshire South Research Ethics Committee and the study is registered with Clini-
calTrials.gov (NCT01541852). The trial flow chart is reproduced in figure 4.1. Longitu-
dinal data are reported as baseline and follow-up 18F-FDG PET/CT scans; the interval
was approximately 16 weeks.
COPD participants were randomised equally to receive either losmapimod or placebo.
The longitudinal data from the participants receiving placebo were used to investigate
repeatability of 18F-FDG PET/CT over 4 months.
EVOLVE was an observational, cross-sectional study of COPD participants, ↵
1
ATD
participants, healthy smokers and healthy never-smokers. Identical study assessments
were performed in both studies (see chapter 3). A single cross-sectional 18F-FDG
PET/CT was performed on participants in this study.
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Figure 4.1: The EVOLUTION trial flow chart.
A baseline and follow-up pulmonary 18F-FDG PET/CT scans occurred approximately 16 weeks apart.
More details of the trial are available [154]. MRI = Magnetic resonance imaging.
4.4.2 Quantitative PET/CT Protocol
The subjects underwent the PET/CT protocol as described in chapter 3. For COPD
and ↵
1
ATD participants a single HRCT was performed, in the longitudinal study this
was performed only at the baseline scan. Subjects were scanned in the supine posi-
tion with arms raised above their heads; at full inspiration, where possible. The FOV
covered the apex to the base of the lungs, with the subjects lungs centred in the FOV.
Table 4.1 summarises the protocols used for HRCT scans for the scanners used in this
study, images were reconstructed using a sharpening algorithm. The effective dose
for the HRCT was estimated as 3.8mSv using the impact dose calculator. Emphysema
burden was calculated from the HRCT scan using the Perc15 score, that is, the 15th
percentile of Hounsfield Units distribution as described previously [156].
Prior to the PET scan, a low dose CT-AC scan, covering a single bed position with
the subject breathing freely was performed. The whole lung fractional air volume, V
a
,
was calculated from the CT-AC. A bolus of approximately 240MBq 18F-FDG was ad-
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Figure 4.2: Flow diagram for participants.
Summary diagram explaining the subject numbers for each of the experiments in this chapter.
COPD = Chronic Obstructive Pulmonary Disease, ↵1ATD = Alpha-1-anti-trypsin deficiency, sHV = Healthy
Volunteer smokers, nsHV = Healthy Volunteer never smokers.
Table 4.1: Acquisition parameters for high resolution CT (HRCT) scans of the lungs for the
two scanners used in this study.
Parameter Scanner A Scanner B
Tube voltage (kVp) 130 120
Tube current (mA) 170 440 (max)
Effective exposure (mAs) 70 440 (max)
Reconstruction B70s Body filter
Slice thickness (mm) 2 1.25
ministered at the start of the scan; the scan duration was 60 minutes.
4.4.3 Image Analyses
In this chapter, the pipeline described in chapter 3 was used for all subsequent analy-
ses except for the reproducibility study (described in section 4.4.4).
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In the reproducibility study, either pipeline A or pipeline B was used, given these la-
bels to distinguish them from the pipeline used in the rest of this thesis. Hence, when
reference to pipeline A or B is made, it should be understood that these have been
used only in the reproducibility study (i.e. results in section 4.5.5); the differences be-
tween the pipelines are described in section 4.4.4.






as surrogate markers of
pulmonary inflammation. Unless otherwise stated SUV refers to the mean SUV in the





4.4.4 Reproducibility of analysis
A subset of 30 age and gender matched patients from the EVOLVE study were in-
cluded in this evaluation: ten patients with COPD (age= 66 ± 9; 8M/2F), ten pa-
tients with ↵
1
ATD (age= 63± 8; 7M/3F) and ten healthy never smokers (age= 68± 8;
9M/1F). For the initial analysis, subject data were analysed by operator A (as de-
scribed in [66]) using a Molecular Imaging and Kinetic Analysis Toolbox (MIAKATTM
[157]; Version no: 4.2.6) based pipeline - referred to as pipeline A. Operator B (LV)
independently analysed the same dataset using the pipeline based on that described
in chapter 3 - referred to as pipeline B. However, again note that the initial pipeline B
is not identical to that described in chapter 3 (the differences are highlighted shortly).
The pipelines shared common procedures for pre-processing: the segmentation of
the whole lung and blood vessels were performed using ITK-SNAP [158], plasma
TACs were obtained from an ROI manually delineated within the descending aorta
(DA); drawn in the centre of the vessel to minimise the partial volume effect. The prin-
ciple differences between the pipelines are outlined in table 4.2. In pipeline A, sub-
sequent analysis was performed using a MIAKAT based pipeline: MIAKAT software
was modified for lung 18F-FDG kinetics by operator A. Importantly, both pipelines





etc.), see chapter 2.
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In order to understand the drivers of any differences in the results, operator B
investigated the salient parts of the analysis methodology, which led to any differences,
and adjusted elements of pipeline B (described later) to improve agreement.
Table 4.2: Comparison of two analysis pipelines used to estimate metabolic rate of 18F-FDG to
assess pulmonary inflammation.
Parameter Pipeline A Pipeline B: Ini-
tial
Pipeline B: Final

















































Optimisation* Local optimum Global optimum As pipeline A


















The table highlights the key differences between the implementations primarily of the compart-
mental model. Parameters not included below were identical between the analysis pipelines.
Columns "Pipeline B: Initial" and "Pipeline B: Final" describes the parameters which were used in
the initial evaluation and the final settings used following adjustments to pipeline B respectively.
* Apply only to compartmental modelling.
ROI = Region of Interest
4.4.5 Statistics
In addition to the methods outlined in chapter 3, the intra-observer repeatability was
assessed using the coefficient of variation (COV) by operator B using pipeline B. Spear-
mans correlation coefficient was calculated. Bland Altman plots were inspected for
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bias following the approach suggested in [159], data were log transformed. The up-
per and lower levels of agreement (uloa and lloa )were calculated as the mean dif-
ference ±2⇥ standard deviation of the difference. In the reproducibility experiment,
as a further complementary measure to the unpaired t-test, group differences were
investigated using the Hedge’s g effect.
4.5 results
Table 4.3 shows the demographics, lung function tests, systemic markers and quantita-
tive CT outcomes for the groups. The total number of evaluable cross-sectional scans
in each subject group was 84 COPD participants, 11 ↵
1
ATD participants, 12 nsHV
and 10 sHV. Four participants (1 COPD, 1 ↵
1
ATD and 2 sHV) were excluded due to
excessive movement on the PET/CT scan.
There was no difference in the smoking pack-years between COPD participants and
smokers (40± 26 vs 37± 19 pack-years respectively, p = 0.36); ↵
1
ATD participants
had smoked significantly less than both these groups (19± 11 pack-years, p < 0.001).
A significant difference was found in the FEV
1
and hsCRP between COPD and
↵
1
ATD subjects compared to never smokers. V
a
was significantly higher in the COPD
and ↵
1
ATD subjects compared to smokers and never smokers; there was no difference
between smokers and never smokers.
Table 4.3: Demographics, clinical and CT imaging measures of the disease and control groups.
COPD (n = 84) ↵
1
ATD (n =11) Smokers (n = 12) Never Smokers (n =10)
Gender (%male) 67 73 58 83
Age (years) 68± 8 62± 8⇤ 62± 6⇤ 69± 7
FEV
1
(L) 1.37± 0.6⇤⇤⇤ 1.47± 0.4⇤⇤⇤ 2.84± 0.56 2.88± 0.6
Fibrinogen (g/L) 3.4± 0.7⇤ 3.1± 0.6 2.8± 0.6 2.7± 0.5
hsCRP (mg/L) 5.2± 7.0⇤ 3.3± 2.3⇤ 2.1± 1.4 1.2± 0.6
WCC (⇥109 /L) 6.54± 1.83 7.01± 2.72 7.28± 2.02 5.84± 1.31
Neutrophils (⇥109 /L) 4.43± 3.6 4.68± 2.47 4.53± 1.45 3.63± 1.11
Perc15 (HU) -889± 54 -942± 18 NA NA
V
a
0.80± 0.05⇤⇤ 0.83± 0.03⇤⇤ 0.73± 0.03 0.72± 0.04
FEV
1
= forced expiratory volume in 1 second, hsCRP = high sensitivity C-reactive protein, Perc15 = 15th percentile
of Hounsfield units distribution, NA = not applicable, V
a
= fractional air volume, WCC = white cell count.
***p<0.001, **p<0.01, *p<0.05 significant difference compared to never-smokers.
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4.5.1 Whole lung 18F-FDG PET imaging endpoints
Patlak graphical analysis outcomes
nK
i
was increased in COPD participants, ↵
1
ATD participants and smokers compared





ATD participants or smokers. Grouping COPD participants
by smoking history revealed that nK
i
was modestly elevated in COPD participants
who were current smokers compared to those who were ex-smokers (4.2± 0.1⇥ 10-3
vs 3.7± 0.1⇥ 10-3ml · cm-3 ·min-1, respectively; p = 0.049) despite no significant
difference in FEV
1
between them (mean FEV
1






were elevated in the smokers without COPD and never-smokers com-
pared to the COPD and ↵
1
ATD participants, there was a modest indication that K
ip
was elevated in the smokers compared to never smokers (p=0.048). There was no dif-
ference in K
ip




In contrast to nK
i
, the group differences in K
im
did not reach significance between
any of the cohorts compared to the never-smoker control group (see figure 4.5a). An
elevated K
im
was observed in smokers compared to COPD participants (p = 0.007)





when compared to smokers and never smokers; there was no statistical
difference in V
b
between smokers and never smokers.
SUV
The SUV was increased in the smokers and never smokers groups compared to the
COPD and ↵
1
ATD cohorts (see figure 4.5); there was no significant difference between
the smokers and never smokers. The SUV was significantly elevated in the COPD
participants compared to the ↵
1
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Figure 4.3: Whole lung nKi,Kip and Vss in disease and control groups.
(a) Whole lung nK
i
.
(b) Whole lung K
ip
.
(c) Whole lung V
ss
.
Individual values are shown along with median, first and third quartile values. SUV is the average
value from the final 30 minutes of the scan. COPD = Chronic Obstructive Pulmonary Disease, ↵1ATD =
Alpha-1-anti-trypsin deficiency, sHV = Healthy Volunteer smokers, nsHV = Healthy Volunteer never smokers.
⇤ p-value < 0.05, ⇤⇤ p-value < 0.01, ⇤⇤⇤ p-value < 0.001, ⇤⇤⇤⇤ p-value < 0.0001
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Figure 4.4: Whole lung Kim and Vb in disease and control groups.
(a) Whole lung Kim.
(b) Whole lung V
b
.
Individual values are shown along with median, first and third quartile values. P-values are indicated
by the horizontal lines (for each group compared to the control group of never smokers). COPD =
Chronic Obstructive Pulmonary Disease, ↵1ATD = Alpha-1-anti-trypsin deficiency, sHV = Healthy Volunteer
smokers, nsHV = Healthy Volunteer never smokers.
⇤ p-value < 0.05, ⇤⇤ p-value < 0.01, ⇤⇤⇤ p-value < 0.001, ⇤⇤⇤⇤ p-value < 0.0001
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Figure 4.5: Whole lung SUV in disease and control groups.
Individual values are shown along with median, first and third quartile values. COPD = Chronic
Obstructive Pulmonary Disease, ↵1ATD = Alpha-1-anti-trypsin deficiency, sHV = Healthy Volunteer smokers,
nsHV = Healthy Volunteer never smokers.
⇤ p-value < 0.05, ⇤⇤ p-value < 0.01, ⇤⇤⇤ p-value < 0.001, ⇤⇤⇤⇤ p-value < 0.0001
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4.5.2 Regional lung 18F-FDG PET imaging endpoints
Between group comparison
Table 4.4 shows the results for 18F-FDG PET imaging endpoints assessed in the upper,
middle and lower regions of the lung in each of the groups. Notably, COPD partici-
pants had increased upper and middle lung nK
i
values compared to never smokers.
Furthermore, ↵
1
ATD participants and smokers demonstrated a similar increase in up-
per and middle lung nK
i
values compared to never smokers. No differences were
found in the lower lung between the cohorts.
In contrast, smokers and never smokers exhibited increased regional K
ip
values com-
pared to COPD and ↵
1
ATD participants but this did not reach significance. K
ip
values
were elevated in the upper and middle lung in smokers compared to never smokers.
K
im
values exhibited no statistical differences between the groups when compared
to the control group across the upper, middle and lower lung. However, in the up-
per lung K
im
values were increased in the smokers when compared to the COPD
and ↵
1
ATD participants (p = 0.002 and 0.006, respectively). V
b
was decreased in the
upper, middle and lower lung in ↵
1
ATD and COPD participants compared to never
smokers. There was no difference in V
b
between smokers and never smokers in any




A within group comparison of 18F-FDG PET imaging endpoints found COPD partici-
pants had elevated K
im
values in the upper and middle lung compared to their lower
lungs (p = 2.1⇥ 10-5 and 2.3⇥ 10-4 , respectively). No within group significant differ-
ences were found between the upper, middle or lower regions in the other endpoints




, SUV). In ↵
1
ATD and COPD participants, V
b
was
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Table 4.4: Regional lung 18F-FDG PET endpoints in disease and healthy participants.
COPD ↵1ATD
Upper Middle Lower Upper Middle Lower
nK
i
















0.11± 0.045⇤ 0.10± 0.036⇤ 0.087± 0.039⇤ 0.11± 0.033⇤ 0.084± 0.034⇤ 0.052± 0.027⇤
Smokers healthy volunteers Never-smokers healthy volunteers
Upper Middle Lower Upper Middle Lower
nK
i
















0.16± 0.043 0.16± 0.053 0.15± 0.07 0.15± 0.027 0.15± 0.027 0.11± 0.031
COPD = Chronic Obstructive Pulmonary Disease, ↵
1
ATD = alpha-1 anti-trypsin deficiency
V
b
= Fractional blood volume, V
ss
= steady state partition coefficient of 18F-FDG.
⇤ indicates a p-value < 0.05 as compared to never-smokers.
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4.5.3 Comparison between 18F-FDG PET endpoints and clinical measurements
In the COPD group, correlation was observed between whole lung nK
i
and fibrinogen
(r = 0.40,p < 0.001), log
10
hsCRP (r = 0.26,p = 0.02), WCC (r = 0.24,p = 0.03) and
neutrophils (r = 0.28,p = 0.01). A modest inverse correlation was observed between
FEV1 (%predicted) (r = -0.22,p = 0.04) and whole lung nK
i
; however, no correlation
was found between nK
i
and 6MWD (r = -0.26,p = 0.15) or emphysema assessed as
Perc15 scores (r = -0.10,p = 0.42). There was no correlation found between the total
smoking pack years and whole lung nK
i
. In contrast to nK
i
, there were no signifi-
cant correlations observed between whole lung K
im
and clinical measurements. SUV
and K
ip
had modest positive correlations with FEV
1
(r = 0.64,p = 1.8⇥ 10-8 and
r = 0.40,p = 0.0005, respectively); no other significant findings were observed.
Given that nK
i
demonstrated several significant correlations with clinical measure-
ments, multiple regression analysis was performed for nKi; this demonstrated that
fibrinogen was independently associated with nK
i
(see table 4.5).
Table 4.5: Variables associated with whole lung nK
i
















= Forced expiratory volume in 1 sec-
ond, hsCRP = high sensitivity C reactive pro-
tein.
4.5.4 Repeatability of 18F-FDG PET
In COPD participants who received placebo, where a follow-up scan was available
(n= 32), the repeatability of whole lung 18F-FDG PET endpoints were assessed. The
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mean difference in nK
i
between the baseline and follow-up was -1.2 ⇥ 10-4ml ·
cm-3 ·min-1 with a coefficient of repeatability (CoR) of 1.8⇥ 10-3 ( see figure 4.6a).




between baseline and follow-up were -8.7 ⇥
10-6ml · cm-3 ·min-1 and 0.0024ml · cm-3, respectively; with CoR of 4.2 ⇥ 10-4




between baseline and follow-up was
-1.5⇥ 10-3ml · cm-3 ·min-1 and -2.9⇥ 10-3, respectively; with CoR of 5.0⇥ 10-3
and 0.057 (see figure 4.6b). The mean difference in SUV was -0.01 with CoR = 0.14.
Expressing these as percentages to allow for easier comparison, the mean values were






and the SUV respectively; the CORs
were 21.5%, 26.3%, 42.2% and 12.2%.
Interestingly, COPD participants who had an exacerbation in the 3 months follow-
ing the baseline scan (since study participants had to be exacerbation free for 1 month
prior to the follow-up scan) exhibited a modest increase in whole lung nK
i
(p = 0.049)
compared to those who did not experience an exacerbation (p = 0.59; see table 4.6).
There was no significant change in the other 18F-FDG imaging outcomes in this exac-
erbation group. V
b
exhibited no change between the baseline and follow-up scans.
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Figure 4.6: Bland Altman plots for whole lung 18F-FDG PET outcomes.
(a) Bland Altman plot of the repeatability of nKi.
(b) Bland Altman plot of the repeatability of K
im
.
Legend: These data were obtained from the baseline and follow-up 18F-FDG scans of COPD
participants in the placebo arm. The interval between scans was approximately 4 months. Dashed red
lines = Upper and lower limits of agreement, dashed blue line = mean of difference.
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Table 4.6: The effect of exacerbation on whole lung 18F-FDG imaging endpoints in COPD
participants. Those that experienced an exacerbation (n=10) and those that did not
(n=22) between baseline and follow-up scans. These are subjects who were on the
placebo arm of the EVOLUTION study.
Exacerbation No exacerbation
Baseline Follow-up Baseline Follow-up
K
im
(ml · cm-3 ·min-1) 6.0± 1.9⇥ 10-3 3.9± 1.8⇥ 10-3 5.0± 1.5⇥ 10-3 4.3± 1.2⇥ 10-3
V
b
0.12± 0.044 0.10± 3.8 0.098± 0.034 0.095± 0.03
K
ip
(ml · cm-3 ·min-1) 5.0± 2.0⇥ 10-4 5.7± 2.4⇥ 10-4 5.0± 1.9⇥ 10-4 4.9± 1.9⇥ 10-4
nK
i
(ml · cm-3 ·min-1) 3.6± 1.1⇥ 10-3 4.1± 1.3⇥ 10-3 3.8± 0.88⇥ 10-3 3.7± 1.1⇥ 10-3
V
ss
(ml/cm3) 0.14± 0.041 0.14± 0.046 0.14± 0.039 0.13± 0.038
V
b
= Fractional blood volume, V
ss
= steady state partition coefficient of FDG.
4.5.5 Reproducibility of analysis
Pipeline A compared to pipeline B
There was poor agreement between K
im
values on a subject level between the
pipelines: figure 4.7(a) shows the Bland-Altman plot for K
im
. The mean difference
in K
im
between the two pipelines was 0.0041 ml · cm-3 · min-1 with upper and
lower limits of agreement (uloa and lloa) of 0.00097 and 0.0072 ml · cm-3 ·min-1
respectively; the correlation coefficient was 0.62 (p < 0.001). Figure 4.7 (a) indicates a
systematic relationship may exist between the difference and the mean values of K
im
estimated using the two pipelines. These data were log transformed, giving a mean
K
im
of 1.8, lloa of 1.19 and uloa of 2.73 (after transformation back to the original scale).
Although the transformation improved the situation, the agreement between pipelines
was still poor.
The poor agreement between K
im
was investigated further, figure 4.8(a) shows




ATD and controls using the two pipelines.
Although a systemic offset was observed between the values obtained between the
pipelines, this did not alter the overall group-level conclusions: the Hedge’s g fac-
tor for the difference between COPD and HV was -0.89 for pipeline A and -0.57 for
pipeline B. Further, for pipelines A and B, no significant difference was found between
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these groups using the two sample t-test (p = 0.088 and p = 0.26, respectively). The
variance in pipeline B was greater than pipeline A in the ↵
1
ATD group (IQR = 0.0031





was -0.0015 (uloa = 0.045, lloa = -0.048); the correlation coefficient was





In comparison, the Bland-Altman plots for the 18F-FDG uptake estimated using Pat-












0.00015 and the correlation coefficients were 0.90 and 0.84, respectively (p < 0.001 in
both cases).
Modified pipeline B
Subsequently, pipeline B was modified to understand the drivers of the difference
described above. Since the differences pertained chiefly to compartmental modelling
outcomes (i.e. K
im
), these were used as the main endpoints to improve the repro-
ducibility. Firstly, visual inspection of the lung tissue TACs from pipeline A and B re-
vealed minimal differences. Further, the mean square error (mse) between lung TACs
from pipeline A and pipeline B was 0.11± 0.040, therefore, the lung TACs were not
responsible for the differences.
Next, a visual inspection of the blood TACs revealed slight differences due to the
ROI methodology (e.g. size and location) used by the two operators. To improve agree-
ment, the same DA ROI methodology was applied: in pipeline B, the area of each ROI
was reduced and the same begin and end axial slice locations as pipeline A were used.
This led to an improvement in the visual comparison of the blood TACs and a modest
improvement in K
im
(mean difference between was 0.0037ml · cm-3 ·min-1 com-
pared to the original value of 0.0041ml · cm-3 ·min-1). The modelling of the blood
TAC was then compared: the fitting of the input functions differed chiefly in the early
stage of the scan (< 5 minutes post-injection) - likely due to the inherent noise due
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Figure 4.7: Bland-Altman plots comparing outcome parameters of a pulmonary compart-
mental model of 18F-FDG.
These are the initial results using two different analysis pipelines. Adjustment of pipeline B led to
improved agreement between the pipelines (see figure 4.11).
to short frame durations. In pipeline B the input function modelling was altered to
match the approach adopted in pipeline A. Firstly, we applied the same fitting func-
tion: here the blood TAC is modelled by basis functions [147] with a varying number
of exponentials; the exponential model that best fits the blood TAC was found using
a least squares algorithm. With both pipelines using this approach, the Bland-Altman







Figure 4.8: Boxplot of group differences in K
im
between two independent analysis
pipelines.
A1ATD = ↵1-antitrypsin deficiency patients, COPD = Chronic Obstructive Pulmonary
Disease, HV = Healthy Volunteer, _A = Pipeline A result, _B = Pipeline B result.
The time delay estimation is also highly dependent on the initial time frames of the
input function; an association between the difference in outcome parameters, particu-
larly V
b
, and the estimated time delay was found. The mean difference in time delay
estimation between pipeline A and B was 3± 5.3 second. To improve the agreement
between the estimated time delays for each subject, in pipeline B the method outlined
in [66] (used in pipeline A) was replicated. Namely, a one compartmental model was
fitted to the first 5 minutes of the smoothed blood TAC and lung TAC. Then a delay of
± 50 seconds in one second increments was introduced and the delay was estimated
by finding the minimum value of the residual sum of squares on the model fit. The
mean difference in time delay estimation was improved to 0.76± 1 second. This im-






Various factors were adjusted in the optimisation algorithm including the function,
number of iterations, tolerance, initial parameter etc. but these were found to have less
influence on outcome parameters. Figure 4.10 summarises the incremental improve-
ment in agreement during each stage of the evaluation as we altered pipeline B. Fol-
lowing all adjustments to pipeline B, the Bland-Altman plots are shown in Figure 4.11;
the mean differences were K
im
= 9.0⇥ 10-4ml · cm-3 ·min-1 and V
b
= -0.0014 with
coefficients of reproducibility of 0.0015 and 0.027. The correlation was also improved:
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Figure 4.9: Bland Altman plots comparing 18F-FDG uptake from two independent operators
using Patlak analysis.
(a) Bland Altman plot of the reproducibility of nKi.
(b) Bland Altman plot of the reproducibility of K
ip
.
These data were obtained from two independent operators and analysis pipelines (A and B). Dashed red
lines = Upper and lower limits of agreement, dashed blue line = mean of difference.
for K
im
, r = 0.86 and for V
b
, r = 0.94. Figure 4.12 demonstrates the improvement in
agreement on a group level. K
im
calculated using the adjusted pipeline B had larger
variability than pipeline A in the healthy control group (IQR = 0.0031 vs 0.0022, re-
spectively); no notable change was observed in any of the other groups (see figure
4.12).
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Figure 4.10: Cumulative Bland-Altman coefficients of reproducibility for K
im
during the
evaluation of pipeline A and B.
Pipeline B was altered at each stage to improve the agreement in K
im
, each value represents the
cumulative effect of all preceding stages.ROI = Region of Interest
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Figure 4.11: Bland-Altman plots comparing outcome parameters of a pulmonary compart-
mental model of 18F-FDG using two independent analysis pipelines following
adjustment of pipeline B.
This should be compared to the initial results in figure 4.7.
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Figure 4.12: Boxplot of group differences in K
im
between two independent analysis
pipelines after adjustment of pipeline B.
A1ATD = ↵1-antitrypsin deficiency patients, COPD = Chronic Obstructive Pulmonary
Disease, HV = Healthy Volunteer, _A = Pipeline A result, _B = Pipeline B result.
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4.6 discussion
In this study we built on prior small studies [54, 55] to test the hypothesis that 18F-
FDG can be used to quantify pulmonary inflammatory burden in COPD patients and
investigated the different analysis methods used to quantify the signal. The main find-
ing is that different analysis methods gave disparate results when comparing 18F-FDG
uptake in COPD, ↵
1
ATD, healthy smokers and never smokers. Nevertheless, a num-
ber of interesting findings were observed which further elucidate the utility of these
contending 18F-FDG PET outcomes. Given that there is no gold standard method to
assess lung inflammation, these results suggest that nK
i
may be a suitable outcome for
COPD, corroborating the pathological understanding of this disease. Besides demon-
strating an increase in COPD participants compared to healthy never-smokers, nK
i
was increased in ↵
1
ATD participants and smokers without COPD. Further, nK
i
corre-
lated modestly with other clinical markers with the strongest correlations observed in
the upper lung. The recent algebraic proof confirms that nK
i
may not be driven pre-
dominately by inflammation as previously assumed, but these results suggest it may
still be a useful composite measure of disease activity. Indeed, in COPD participants
who experienced an exacerbation ( 1 month prior to the follow-up scan) there was a
residual increase in nK
i
as detected by 18F-FDG PET. However, further work is needed
to explore whether nK
i
reflects inflammation.
Previous studies have highlighted that static 18F-FDG PET measurements such as
SUVs within the lung may be influenced by radioactivity in the blood vessels and air
within lung spaces [24]. In our data, the whole lung SUV was increased in healthy con-
trols compared to patients; indicating that it is unsuitable for evaluating lung disease
in the context of COPD. Given that V
b
was increased in never smokers and smokers
compared to COPD patients, the increased SUV signal may be driven to a large ex-
tent by blood volume. The increased V
a
found in COPD and ↵
1
ATD due to tissue
destruction is likely to be another factor reducing SUVs in the patient groups, and is
consistent with previous findings in IPF patients [60]. These two factors likely explain
the observed positive correlation between SUVs and FEV
1
in COPD patients. Never-
theless, other investigators found that the SUV was sensitive to low levels of induced
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inflammation in healthy volunteers and so response to therapy [30], however, our re-
sults suggest in diffuse lung diseases when substantial tissue destruction is present,
whole lung SUVs may be inadequate. An air-fraction correction for the SUV has been
suggested [53] but the result may still be biased by the concentration of 18F-FDG in the
blood and is less sensitive to density mismatches [114]. Similarly, K
ip
derived using
Patlak analysis, showed increased values in the smokers and non-smokers compared
to the COPD and ↵
1
ATD participants (see figure 4.4b), these data indicate that as
a measure of disease activity, K
ip
is incongruent with the pathophysiological under-
standing of these diseases.
Using nK
i
, elevated whole lung values were observed in ↵
1
ATD and COPD par-
ticipants compared to never smokers, consistent with the understanding that lung
damage is driven by inflammation. Chronic inflammation is a key trait of smoking
and the association of nK
i
with smoking agrees with previous early observations [91].
These findings were observed in smokers without airflow limitation (smokers vs never-
smokers) despite similar tissue density. Given that 18F-FDG PET signal likely reflects
a composite of total immune cell response, this may explain the comparable levels
of 18F-FDG in smokers with and without COPD consistent with the poor association
between airway neutrophilia and airflow limitation.
nK
i
values were elevated in ↵
1
ATD participants compared to the never-smokers
group; in contrast to findings previously reported by others [54], but our results
are consistent with the understanding of pathological pathways underlying ↵
1
ATD,
specifically that lung damage is driven by increased neutrophilic inflammation. There
was a modest yet significant correlation between whole lung nK
i
values in COPD
participants and circulating plasma fibrinogen. Given that previously no strong asso-
ciations were found between markers of systemic inflammation (including fibrinogen)
and vascular inflammation [155], these data do suggest, for the first time, that in-
creased plasma fibrinogen observed in COPD participants may relate to the burden of
pulmonary inflammation. Fibrinogen may be more reflective of exacerbation risk than
other systemic markers (i.e. hsCRP, WCC and neutrophils) and this further supports
its relevance as an FDA and EMA qualified drug development tool assessing risk for
exacerbation and mortality in COPD [160]. In vitro studies suggest that pulmonary
74
18
f-fdg pet/ct in chronic obstructive pulmonary disease
epithelium can be an extrahepatic source of fibrinogen in response to local inflam-
matory mediators [161, 162]. However, fibrinogen is a putative biomarker and there
is not currently enough evidence to support its use as a clinical measures of disease.
The correlation between nK
i
and neutrophil count, although weak, is of particular
interest, since it is consistent with the previously held hypothesis that the 18F-FDG
signal may be driven primarily by neutrophil migration and activation [163]. How-
ever, 18F-FDG uptake is likely to be a composite of the total immune response given
previous findings in asthmatic participants that have demonstrated its use as a marker
for eosinophilic inflammation [58]. Therefore, care is needed when attributing the ori-
gin of the signal to a specific cell line.
In principle compartmental modelling enables isolation of the 18F-FDG PET signal






is thought to be an accurate estimate of
metabolic rate of 18F-FDG in lung cells [30]. Therefore, as an outcome measure it may
be more specific to the disease process, namely the inflammatory lung cells. A previ-
ous smaller study of COPD using 18F-FDG PET found that compartmental modelling
derived imaging endpoints had increased values in the lung compared to healthy con-
trols, whereas Patlak outcomes found no differences [164]. In that study, an alternative
methodology was used involving a retrospective correction for pulmonary blood and
air; it has been suggested that this method may overestimate values in regions with
vanishingly small tissue fractions, which are common in emphysematous disease [66].
Disappointingly, our results showed no significant differences between the groups
using K
im
when compared to the control group in both whole lung and regional anal-
yses. This confirms the recent suggestion that K
im
may not be sensitive enough to
detect underlying metabolic differences in the disease process in COPD patients [66].
Indeed, in the COPD patients there was no evidence of association between K
im
and
clinical measures of disease. Interestingly, it did identify increased metabolic rate in
smokers compared to COPD participants but not compared to never smokers, this
latter finding is difficult to interpret. Indeed, in the small proportion of subjects who
exhibited an exacerbation within 3 months of the baseline scan, K
im
values exhibited
a decrease in the follow-up scan, given the role of inflammation in exacerbations [165]
this is another discordant finding. In contrast, nK
i






between baseline and follow-up. This was evident despite a mini-
mum one month period prior to the follow-up scan.





ATD and healthy smokers compared with the up-
per lung in healthy non-smokers. In addition, there was a correlation between upper
lung emphysema (assessed by perc15) and nK
i
in COPD participants. This is consis-
tent with previously reported results which showed a regional predilection for uptake
which correlated with disease [54] however, an increase in middle and whole lung nK
i
was also observed. This appears to agree with the nascent understanding of the dif-
ferential regional immune responses in asthmatic patients. No lower lung differences
were observed, it is possible that partial volume effects from diaphragm motion were
responsible . K
ip
did not demonstrate any significant regional differences between the
groups. Equally, the regional comparison of K
im
revealed no differences across the
groups, in keeping with the findings in the whole lung.
The repeatability of whole lung 18F-FDG PET endpoints in COPD patients on the
placebo arm of the EVOLUTION trial was assessed. The Bland-Altman analyses re-











). This is consistent with find-
ings in a smaller study of COPD subjects using 18F-FDG PET which reports the re-
peatability of the imaging endpoints over a 4 week period [164]. Although in that
work the author reports good repeatability for all the outcomes, it is clear from the
Bland-Altman plots that the compartmental modelling outcomes have poorer agree-
ment between the two imaging visits. In the results reported here, V
b
in particular
exhibits a large variance; this may be due to the noise in the initial time frames of
the PET scan. The estimation of Patlak outcomes does not require the data points
corresponding to these initial time frames and involves fitting fewer parameters. This
may also partly explain the improved reproducibility of the analysis methods found
in Patlak analysis compared to compartmental modelling. Moreover, Patlak analysis is
more easily standardised than compartmental modelling; there are fewer parameters
to select and as it is linear model, hence will have only one solution (corresponding
to a single minima). The SUV had superior repeatability compared to other outcomes
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and is similar to previously reported values using 18F-FDG [166] and other tracers
[167].
For compartmental modelling, the initial results of the reproducibility experiment




; despite the application of the
same model. Interestingly, this did not change the overall interpretation of the group
findings; the effect size between groups was comparable using either pipeline. Fur-
ther, it did not change the outcome of statistical hypothesis testing between groups.
Reproducibility of analysis is an important pre-requisite for an imaging biomarker;
the results of this evaluation demonstrate the need for standardisation when apply-
ing compartmental modelling to assess lung inflammation. The salient factors in these
data were the blood ROI methodology, input function modelling and time delay es-
timation. By adjusting the blood ROI definitions, the input function fitting method
and the time delay calculation in pipeline B, the results demonstrate better agreement
between the two pipelines (see figures 4.8, 4.12 and 4.11) and on a similar level to the
agreement found using Patlak analysis in the first case. Currently there is no standard
method of assessing pulmonary inflammation using compartmental models of 18F-
FDG and each centre may undertake such analyses using their own bespoke approach.
These findings suggest that despite seemingly similar methodology, individual subject
results are sensitive to several factors in the implementation of the methodology, there-
fore care is needed when reporting the exact methods used.
Limitations
There were limitations in this study including inaccuracies introduced by the align-
ment of the PET and CT images: CT-AC were acquired under free breathing, this may
lead to inaccuracies when quantifying the PET scan due to mismatch between PET
and CT. Further, this can be exacerbated by changes in lung density due to respiratory
phase [114].
Exacerbations in the COPD participants prior to the study may have confounded
the interpretation of the quantitative 18F-FDG PET data, since the recovery period to
return to a baseline has yet to be elucidated; this also has implications for the find-
ing that nK
i
was increased following an exacerbation. The study was not formally
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powered based on secondary endpoints (e.g. 6MWD, Perc15) therefore, it may be un-
derpowered leading to insufficient data to assess these endpoints robustly.
The analyses were performed in retrospective studies, this limited the possible anal-
yses undertaken; for example, it was not possible to estimate the influence of acqui-
sition parameters on imaging endpoints. As mentioned previously, there is no gold
standard method to validate the various outcome measures against tissue inflamma-
tion, instead the approach adopted here involved evaluating the technical and clinical
validity of the outcome measures.
The 18F-FDG PET scans were performed in a heterogenous set of COPD participants
with a range of emphysematous burden, the whole lung analyses in particular could
have been influenced by the varying severity of emphysema. Further work will be
needed to determine the impact of emphysematous changes on 18F-FDG PET analy-
ses.
Estimates of reliability may vary with specific image acquisition parameters, scanner
characteristics and data processing; hence, comparisons with other studies is challeng-
ing. Nevertheless, by analysis of participants allocated to placebo in the EVOLUTION
trial, the repeatability of quantitative 18F-FDG PET outcomes was quantified. More-
over, the reproducibility of the dynamic 18F-FDG outcomes were assessed using two
independent pipelines. Since both operators used the same reconstructed datasets, this
does not include within subject biological variability or technical factors (e.g. scanner
settings & reconstruction algorithms), which would allow the overall reproducibility
to be evaluated. Nevertheless, with each operator using identical scans, the system-
atic variability in 18F-FDG uptake introduced by differences between hardware, recon-
struction and acquisition protocols was avoided [168]. Harmonisation of acquisition
and analysis protocols in diffuse lung disease should be established for future PET
studies.
The POB ratio was calculated for each subject using discrete venous blood samples;
this allows the conversion of a blood input function to a plasma input function; this
may cause bias in the outcome variables. The POB ratio was found to be very close to
78
18
f-fdg pet/ct in chronic obstructive pulmonary disease
one (1.05± 0.03), this agrees with previous findings that 18F-FDG equilibrates between
erythrocytes and plasma nearly instantaneously [169]. Further work should determine
whether POB corrections are necessary in quantitative 18F-FDG lung studies.
Previous work has demonstrated that the weighting factors chosen to describe the
variance of dynamic PET data affects the outcomes of compartmental modelling [170].
In the reproducibility experiments, the impact of different weighting schemes was not
explored but this could be another key contributor which may improve reproducibility.
The inter-observer effect could not be assessed as results from pipeline A, undertaken
by operator A, were retrospectively acquired. Yet, the salient stages of compartmen-
tal modelling which were responsible for the low concordance observed between the
pipelines were identified.
The findings of this chapter highlight that interpretation of lung 18F-FDG uptake
is challenging due to the presence of air and blood which vary with disease burden.
Investigators have used SUVs, PGA and CM in previous studies to analyse 18F-FDG
uptake. The observation that COPD participants had a sustained signal in the longitu-
dinal study indicates the stability of 18F-FDG uptake. Despite the nascent understand-
ing that nK
i
does not represent lung tissue uptake alone, it has shown promise as
a composite marker of disease and corroborates previous findings in smaller groups.
Interestingly, when comparing the smokers and healthy never smokers, which have




or airflow limitation, only nK
i
found a difference
consistent with the understanding of increased inflammation due to smoking [91]. Fur-
ther, it had a modest, yet significant, correlation with markers of disease severity and
a lower variability than K
im
. Repeatability and reproducibility were also improved in
Patlak analysis compared to compartmental modelling. Disappointingly, compartmen-
tal modelling - which directly accounts for air and blood- did not reveal any signifi-
cant differences between groups or associations with clinical measurements. Based on
the findings of this chapter, further evidence is required before considering 18F-FDG
imaging endpoints as useful biomarkers to assess lung disease in COPD. Indeed, the
observations in this chapter demonstrate that investigators using quantitative 18F-FDG
in future studies of COPD would need to carefully consider the method of analysing
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images and the impact that differences in lung architecture can have on the imaging
endpoints. Moreover, there is an assumption that these measures of 18F-FDG uptake
relate to underlying inflammation, but further work is needed to validate these mea-
sures against lung cell counts in diseased individuals.
4.7 conclusion
There are substantial challenges when using 18F-FDG PET to assess lung disease in
COPD, underlined by the disparate findings using different PET analysis outcomes
observed in these data. The disparity appears exacerbated in COPD due to the varying
severity of emphysema. The observations made here exemplify the need for careful
study design when using 18F-FDG PET to assess lung disease in COPD, especially
when justifying the image analysis endpoint. There is no gold standard method to as-
sess lung inflammation; nevertheless, our results suggest 18F-FDG uptake quantified
by nK
i
relates to relevant clinical measures of disease, is consistent with the patho-
physiologic understanding of COPD and has good technical validity. However, nK
i
should be used judiciously as it is does not reflect 18F-FDG metabolism alone, but is
influenced by pulmonary blood and air. For example, when comparing groups with
different fractional blood volumes, nK
i
should not be considered as a biomarker of
inflammation without further supportive evidence such as independent blood vol-
ume measures. In addition, tissue validation of the 18F-FDG imaging outcomes will
be helpful to further assess their validity in the context of lung inflammation. Further
evidence is required to evaluate whether 18F-FDG PET imaging outcomes would be a
useful biomarker for COPD; aspects of this will be explored in chapter 5 .

5
S U B T Y P E S O F C O P D B A S E D O N C T I M A G I N G : A S S O C I AT I O N
W I T H D I S E A S E A C T I V I T Y U S I N G 1 8 F - F D G
One of the most significant challenges to improving outcomes and quality of life in
COPD is clarifying the myriad of underlying phenotypes. Existing classifications such
as GOLD, are often based primarily on spirometry, symptoms and exposure to poten-
tial pathogens but these have shown poor correspondence for treatment responders.
New methods are needed to identify sub-types with similar prognostic and thera-
peutic benefits [171], better understanding of the heterogeneity of COPD will have
important implications for management [172]. There has been growing appreciation
of the potential role imaging could play, particularly providing quantitative, regional
measures reflective of underlying disease mechanisms [173].
CT imaging and pathologic findings confirm a range of patterns of emphysema
are present in COPD, even in patients with similar levels of physical impairment. CT
has been validated as a tool for assessment of emphysema with destructive changes
detectable in the hounsfield unit (HU). Initial findings suggested that regions with
a threshold value of < - 9 1 0 HU on CT are emphysematous and was confirmed
by pathological samples [174]. Subsequently, several investigators have explored the
optimal HU threshold, with a value of - 9 5 0 HU now widely accepted. Alterna-
tively, frequency histograms of the HU values in the lung have been used to quantify
emphysema; the 15th percentile value is the most widely reported [175]. In addition,
bronchial and small airways disease (SAD) is readily identified from CT either directly
or using processing techniques, along with other common features such as bronchiec-
tasis and interstitial lung abnormalities.
Visual and quantitive CT can provide complementary methods to assess COPD and
may help to generate sub-types to optimise treatment. To that end, a visual classifi-
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cation system was proposed by the Fleischner Society which classifies patients based
on the patterns of emphysema, airways disease and associated features; subsequently,
the sub-types with severe disease were shown to be associated with increased risk of
mortality even after adjusting for quantitative CT measures [176]. Building on this,
a recent study confirmed a difference in overall mortality in these groups and fur-
ther revealed that certain groups were at more risk of progression [177]. The authors
suggested that the combination of CT features reflect different underlying pathologic
processes.
In this study, the primary aim was to investigate whether these CT subtypes are
associated with underlying pulmonary disease activity assessed with 18F-FDG PET.
Secondly, using longitudinal 18F-FDG PET scans, treatment response within these
imaging subtypes was explored for COPD patients. Finally, to further evaluate 18F-
FDG PET outcomes minimising the influence of emphysema, the 18F-FDG uptake in
COPD subtypes defined by trace emphysema was compared to healthy smokers with-
out COPD and healthy never smokers.
5.1 hypotheses
COPD subtypes defined by visual and quantitative CT are associated with varying
degrees of pulmonary inflammation as assessed by 18F-FDG PET.
5.2 aims
The primary aim was to compare lung inflammation (using quantitative 18F-FDG PET)
between radiologic sub-types of COPD; the subtypes were based on visual and quan-
titative assessment of HRCT scans. Associations between emphysema severity and
disease activity using 18F-FDG PET were explored. A secondary aim was to investi-
gate if differences in treatment response could be identified in these subtypes of COPD
using longitudinal 18F-FDG PET scans. Finally, different 18F-FDG PET outcomes were
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assessed in a single subtype defined by the mildest disease- thus minimising the con-
founding influence of emphysema- and compared to smokers and never-smokers.
5.3 methods
5.3.1 CT subtyping
HRCT scans were performed as described in chapter 4, the scans were reviewed by
a radiology registrar using the HOROS imaging platform [178] after an initial period
of training by an experienced thoracic radiologist. Each COPD participant scan was
categorised according to the Flesichner society statement [179]; table 5.1 summarises
the sub-types. The thoracic radiologist provided oversight by reviewing the resulting
classifications.
Table 5.1: Definitions of COPD subtypes using CT⇤ .
Subtype Location Appearance
Trace CLE Upper lobe pre-
dominant
Minimal centrilobular lucencies, oc-
cupying < 0.5% of a lung zone
Mild CLE Upper lobe pre-
dominant
Scattered centrilobular lucencies,
involving estimated 0.5 - 5% of a
lung zone
Moderate CLE Upper lobe pre-
dominant , dif-
fuse
Many well-defined centrilobular lu-
cencies, > 5% of any lung zone




cencies, multiple regions spanning
several secondary lobules, but not
involving hyperexpansion of sec-
ondary lobules or distortion of pul-
monary architecture
ADE Lower lobe pre-
dominant , dif-
fuse
panlobular lucencies, with hyper-
expansion of secondary lobules
and distortion of pulmonary archi-
tecture
PLE Lower lobe pre-
dominant
Generealised destruction of all




Emphysema is defined by > 6% of pixels with < -950HU on CT.
* Condensed version of definitions, full descriptions available from [179].
ADE = Advanced destructive emphysema, CLE = centrilobular emphysema, PLE = pan-
lobular emphysema
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5.4 results
5.4.1 Overall comparison of CT subtypes
Baseline HRCT scans were reviewed twice in a total of 69 COPD participants according
to the categories in table 5.1. The largest group was ADE with 20 subjects, followed
by mild and trace categories both with 15 subjects (see figure 5.1). The demographics,
clinical characteristics and imaging data of the groups are shown in table 5.2. There
were subjects with predominant airways disease, a secondary pattern of paraseptal
emphysema was identified in 16 subjects. Due to the small number of total subjects,
only primary patterns are subsequently analysed. Equally, only a small number of
subjects with panlobular emphysema (n = 4) were found, these were not included in
subsequent analysis.
Figure 5.1: COPD subtypes defined by CT chest scans using Fleischner guidlines.
Incomplete indicates that paired baseline and follow-up 18F-FDG PET scans were not available, shown
are the number of subjects on placebo or treatment drug, Losmapimod.
ADE = Advanced destructive emphysema, CLE = centrilobular emphysema, light blue box = one of the COPD
subtypes
Physical function, characterised by the 6WMD and FEV
1
values, were lowest in
the confluent CLE and ADE groups. There was an overlap in some of the clinical
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Table 5.2: Demographics, clinical characteristics and whole lung imaging endpoints for sub-
types of COPD.
Trace Mild Moderate Confluent ADE p-value *
CLE CLE CLE CLE
(n = 15) (n = 15) (n = 10) (n = 9) (n = 20)
FEV
1
(L) 1.8± 0.52 1.4± 0.46 1.5± 0.73 1.05± 0.46 0.99± 0.30 < 0.001
Current smoker (%) 7 11 20 11 10
Pack years (yrs) 35± 13 35± 11 39± 12 44± 13 42± 6 ns
6MWD (m) 478± 115 377± 81 375± 98 335± 145 343± 104 < 0.05
Perc15 -833± 32 -865± 24 -890± 35 -918± 18 -949± 41 < 0.001
V
a
0.75± 0.037 0.78± 0.027 0.79± 0.051 0.82± 0.018 0.84± 0.033 < 0.001
V
b
0.13± 0.038 0.12± 0.038 0.11± 0.031 0.08± 0.018 0.08± 0.019 < 0.001
K
im
(ml/min-1/cm-3) 5.5± 1.3 4.9± 1.9 6.8± 4.1 5.3± 0.67 5.1± 1.6 ns
K
ip
(ml/min-1/cm-3) 0.61± 0.1 0.46± 0.12 0.57± 0.25 0.48± 0.15 0.43± 0.19 ns
nK
i
(ml/min-1/cm-3) 3.7± 0.8 3.3± 0.8 3.9± 1.3 4.0± 1.3 4.0± 1.1 ns
SUV 0.53± 0.12 0.47± 0.09 0.49± 0.14 0.39± 0.03 0.34± 0.13 < 0.001
* overall comparison between all 5 groups.
6MWD =six minute walk distance.ADE = advanced destructive emphysema, CLE = centrilobular emphysema ,
FEV
1
= forced expiratory volume in one second
characteristics of the groups; for example, 6MWD in mild and moderate sub-types.
Consistent with spirometry, CT imaging measures (i.e. V
a
and Perc15 values) were
significantly different in the confluent CLE and ADE groups compared to the other
groups indicating more severe emphysema. The SUV was significantly elevated in
the trace, mild and moderate CLE groups when compared to ADE. Additionally, the
SUV was increased in the trace CLE group compared to confluent CLE. In contrast,









decreased in the ADE group compared to trace, mild and moderate CLE; they were
also decreased in the confluent CLE group when compared to trace or mild CLE.
5.5 treatment effects
To investigate whether Losmapimod reduced pulmonary inflammation in each of the
COPD sub-types, 18F-FDG PET outcomes were adjusted for baseline values and values
compared to the placebo group. The number of subjects on treatment and placebo
within the CT sub-types were small in some of categories (figure 5.1). Figure 5.2 and
5.3 shows the plots for the effect of treatment on COPD subtypes using the different
18F-FDG PET outcomes. There were no significant differences between the placebo
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. Notably in the
trace COPD sub-type only, the SUV was significantly elevated in the treatment group
compared to placebo group (p = 0.013), despite no difference in V
b
. Moreover, with
the exception of the SUV, moderate and confluent subtypes demonstrated the largest
differences between placebo and treatment arms in the follow-up imaging endpoints.
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(a) Treatment effect using K
im
.
(b) Treatment effect using nK
i
.
(c) Treatment effect using K
ip
.
Figure 5.2: Effect of treatment on whole lung dynamic PET endpoints in each COPD sub-
type.
The follow-up PET outcome was adjusted for the baseline value using an ANCOVA model.






, (d) SUV .
ADE = Advanced destructive emphysema, blue line = placebo group, yellow line = treatment group.
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Figure 5.3: Effect of treatment on whole lung SUV in each COPD subtype.
The follow-up SUV was adjusted for the baseline value using an ANCOVA model.
Y-axis is the estimated marginal means for SUV .
ADE = Advanced destructive emphysema, blue line = placebo group, yellow line = treatment group
⇤ p-value < 0.05, ⇤⇤ p-value < 0.01, ⇤⇤⇤ p-value < 0.001.
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5.5.1 18F-FDG PET outcomes in trace emphysema compared to controls
Baseline 18F-FDG PET outcomes were assessed in the trace emphysema group (n =15)
compared to the never smokers (n = 10) and smokers without COPD (n = 12). There




between the groups (p = 0.75, 0.45 and 0.15; see
table 5.3). The SUV was highest in the never smokers but there was no significant
difference between any of the groups. K
ip
was elevated in the smokers compared
to the trace COPD sub-type (p = 0.021) and never smokers (p = 0.043). In contrast,
nK
i
was elevated in the smokers compared to the never smokers (p = 0.011), nK
i
was
modestly increased in the trace group when compared to the never smokers (p = 0.04);
there was no difference between smokers and trace (p = 0.25). K
im
values exhibited
no differences between groups (p > 0.5).
Table 5.3: Comparison of PET and CT outcomes in COPD subjects with trace emphysema.
Outcome⇤ COPD (trace⇤⇤) Smokers Never-Smokers P-value⇤⇤⇤
V
a
0.75± 0.039 0.73± 0.040 0.71± 0.041 ns
V
b
0.13± 0.038 0.15± 0.051 0.14± 0.025 ns
K
im
(ml/min-1/cm-3) 5.3± 1.3 7.2± 2.8 6.0± 1.9 ns
K
ip
(ml/min-1/cm-3) 0.59± 0.12 0.77± 0.21 0.61± 0.13 < 0.05
nK
i
(ml/min-1/cm-3) 3.7± 0.8 4.1± 1.2 2.9± 0.54 < 0.05







values reported as ⇥10-3
** trace emphysema as defined in table 5.1
*** P-value reported as difference across all groups
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5.6 discussion
In this chapter, the clinical, physiologic, and imaging characteristics of COPD sub-
types - classified by visual and quantitative chest CT - were investigated. Previously,
such categorisation has shown that the presence and degree of emphysema is associ-
ated with increased mortality risk in COPD subjects [176]. This work investigated, for
the first time, the underlying disease activity in these sub-types of COPD using 18F-
FDG PET. Differences were found in clinical and radiological characteristics between
the sub-types. Although no differences in disease activity were observed between sub-
types using dynamic 18F-FDG PET outcomes, the SUV findings demonstrate that dif-
ferences between groups are detectable using 18F-FDG PET. Further, these data suggest
that when evaluating the performance of novel anti-inflammatory drugs in COPD, un-
derstanding the heterogeneity of response using 18F-FDG PET/CT may be enhanced
by CT image sub-types.
There were clear differences in air-flow obstruction and functional capacity with
increasing emphysema burden, congruent with previous studies in large cohorts of
COPD subjects [176]. Previous studies have found that visual classification of emphy-
sema grade in COPD is a valid discriminatory tool. In a large study of 4000 cigarette
smokers from COPDgene, direct application of the Fleischner guidelines revealed
strong evidence that a worsening grade of emphysema was associated with increased
mortality [176], independent of quantitive severity of emphysema, with adjusted haz-
ard ratios increasing from 1.7 for trace emphysema to 4.1 for ADE. Besides using a
more precisely defined visual grading system, their findings confirmed previous ob-
servations [180, 181] whilst also identifying an independent mortality effect from vi-
sual classification. Later work based on the Fleischner grading system evaluated 9080
current and former smokers from the COPDgene study. In addition to confirming that
mortality differed between COPD sub-types, the investigators further found distinct
discordant subtypes; for example, those with visual but not quantitative emphysema
which exhibited greater progression of emphysema [177]. The authors suggest that
inflammation of parenchyma or airways may be responsible despite relatively mild
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disease.
The finding that SUV was elevated in those groups with milder emphysema indi-
cates that there may be increased pulmonary inflammation compared to sub-types
with more severe emphysema. However, it is possible that this signal reflects the dif-
ferences in fractional tissue and blood volumes rather than inflammatory burden per
se. Indeed, the SUV for these milder emphysema sub-types is comparable to that of
never-smokers and the dynamic 18F-FDG outcomes were unable to detect differences
between the sub-types. It is possible that these measures are not sensitive enough
to detect subtle differences in inflammation between sub-types. However, in larger
COPD cohorts other investigators have suggested that a distinct CT imaging sub-type
with visual-only emphysema may be characterised by increased inflammation [177].
Future work that refines CT imaging sub-types may reveal greater inflammatory bur-
den in specific sub-types. Although overall the 18F-FDG PET measurements did not
find strong evidence of a difference between groups, measures relating to healthy lung




and perc15 - significantly decreased with worsening severity
of emphseyma.
To investigate treatment response in the COPD subtypes, 18F-FDG PET scans post
treatment with Losmapimod were adjusted for baseline and compared to the placebo
group. Previous studies in this COPD cohort found that losmapimod did not attenuate
vascular inflammation nor did it improve endothelial function [155]. The SUV analysis
revealed that 18F-FDG uptake increased significantly in the treatment group compared
to the placebo group for those with minimal emphysema. There were no differences in
exacerbations or smoking history between the placebo and treatment cohorts thus, it is
difficult to interpret this finding. Importantly, when comparing longitudinal PET/CT
scans in the same subject the influence of air volume on SUV is likely to be less im-
portant, provided the interval between scans is short compared to emphysematous
changes. Nevertheless, the results indicate that when evaluating alternative targeted
therapies, imaging sub-types may provide additional value by identifying differences
in treatment response.
92 subtypes of copd based on ct imaging : association with disease activity using 18 f-fdg
In the previous chapter, emphysema was found to cause discordant results using
the different 18F-FDG PET outcomes. To investigate the relationship between quanti-
tative 18F-FDG whilst minimising the influence of emphysema, COPD patients with
trace emphysema were compared to smokers without COPD and never-smokers. Im-
portantly, there were no statistical differences in pulmonary blood volume and air
fraction between the trace group, smokers and never-smokers. Consistent with the
previous findings (see chapter 4) and the physiological understanding of inflamma-
tion, nK
i
was elevated in smokers and trace COPD compared to never-smokers. Inter-
estingly, K
ip
values were increased in smokers compared to trace emphysema COPD
subjects, but there was no difference between trace emphysema COPD subjects com-
pared to never smokers. Using K
im
or the SUV did not reveal a difference between
the subtypes. Based on this and previous findings, the SUV appears less reliable when
comparing inter-subject differences. The lack of significance found with K
im
indicates
that it may not be sensitive enough in diffuse lung diseases like COPD, similar to ob-
servations in chapter 4, K
im
is more variable than other measures and it is likely that
the noise in this parameter estimation is limiting its power to detect the underlying
inflammatory signal.
There were limitations in this study. Although the initial cohort of COPD subjects
was large for an 18F-FDG PET study, the division into smaller groups led to small
subject numbers reducing the statical power to detect changes. Indeed, the study pop-
ulation was too small to identify enough patients with paraseptal emphysema (PSE)
or airways disease as the predominant pattern. Nevertheless, it was possible to iden-
tify statistical differences between the main CLE sub-types. There was an overlap of
clinical features between the sub-types, in particular the mild and moderate groups,
indicating that these were not isolated clusters of subjects; this overlap has been ob-
served in similar studies using imaging sub-types [176, 177]. However, in this study




In conclusion, dynamic 18F-FDG PET imaging outcomes did not identify differences
in disease activity between sub-types based on CT chest imaging. The SUV demon-
strated an increase in disease activity in milder emphysematous disease but this may
be driven by underlying tissue volume differences rather than inflammatory activity.
These data did show distinct differences in clinical, physiologic and CT imaging char-
acteristics between the COPD subtypes. Treatment with Losmapimod did not reduce
pulmonary 18F-FDG uptake in individual sub-types. In addition, when the influence
of emphysema on quantitative PET was minimised, Patlak analysis revealed increased
uptake between COPD and smokers without COPD compared to never-smokers.
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L U N G I N F L A M M AT I O N I N S A R C O I D O S I S
6.1 introduction
Sarcoidosis is a multi-organ disease of unknown aetiology; the most commonly af-
fected organ is the lung [182]. Sarcoidosis is a disease which is characterised by the
formation of inflammatory granulomata and can be complicated by progressive fibro-
sis and scarring. Despite progress in understanding of the etiopathogensis [183], there
are no specific treatments and new treatment strategies are urgently needed [184].
Moreover, biomarkers which can assess disease activity and identify at risk patients
have remained elusive. To date, 18F-FDG-PET/CT has had a limited role in the clinical
evaluation of sarcoidosis, usually it is reserved for cases where there is diagnostic un-
certainty, i.e. suspected cardiac sarcoidosis [185]. Nevertheless, it has been recognised
that there is a potentially important role for 18F-FDG-PET in management of sarcoido-
sis and assessing treatment effect [186–189].
Several studies have identified that 18F-FDG-PET is a useful tool for assessing inflam-
matory activity in sarcoidosis [187, 188, 190–194]. In a study of 49 newly diagnosed
patients, investigators found that 18F-FDG uptake predicted deterioration in lung func-
tion in untreated patients [192]. The majority of studies have used SUVmax to assess
18F-FDG uptake; recently, other metrics have been investigated such as the total lung
glycolysis (TLuG) [195]. However, the TLuG was equivalent to SUVmax in predicting re-
sponse to therapeutics. Other investigators have sought associations between 18F-FDG
uptake and serological inflammatory markers, particularly angiotensin converting en-
zyme (ACE). Results have been mixed: an early study found no correlation between
18F-FDG uptake and ACE [186], later studies found patients with visually confirmed
positive 18F-FDG findings had elevated ACE levels compared to to those with negative
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results [196]. However, in nearly 50% of those with positive 18F-FDG the ACE levels
were normal. Currently there are no reported studies using dynamic measures of 18F-
FDG-PET to investigate pulmonary sarcoidosis.
Although quantitative 18F-FDG has been used to assess lung inflammation in dis-
eases such as idiopathic pulmonary fibrosis (IPF) [60], acute lung injury (ALI) [24]
and chronic obstructive pulmonary disease (COPD )[55], few studies have provided a
measure of clinical validation. This is partly due to the challenge of obtaining a gold
standard measure of pulmonary inflammation. In a canine model of ALI, a correlation
between rate of 18F-FDG uptake, K
ip
, using Patlak graphical analysis and [3H]DG up-
take in bronchoalveolar fluid (BALf) cells was found [197]. However, they found no
correlation between total cell or neutrophil concentration from BAL fluid. Building on
this, a few subsequent studies of a human model of ALI used endotoxin instilled into
a single lung lobe with the contralateral lung lobe used as a control [23, 24, 65]. How-
ever, using cell counts from BALf, there was not strong evidence that the 18F-FDG PET
signal in the treated lung was driven by neutrophils alone and further murine studies
suggested that other cells were implicated (e.g. macrophages, epitheilal cells) [198]. To
our knowledge, no studies have been performed to assess static and dynamic 18F-FDG
outcomes against inflammatory cells in a clinically relevant diffuse lung disease.
In this study, pulmonary inflammation was assessed in sarcoidosis patients with
clinically active disease using 18F-FDG-PET. The primary aim was to investigate static
and dynamic measures of pulmonary 18F-FDG uptake in sarcoidosis compared to
age- and gender-matched healthy controls. Secondly, associations between 18F-FDG
outcomes, systemic clinical markers of inflammation and pulmonary inflammatory
cell counts from BAL fluid were sought. Finally, in a further development for this




Sarcoidosis patients will have an increased pulmonary 18F-FDG-PET signal compared
to healthy controls; outcomes derived from the dynamic acquisition of 18F-FDG will
further improve the distinction between these groups.
6.3 aims of the study
The principal aim of this work was to compare the pulmonary 18F-FDG uptake in sar-
coidosis patients to healthy controls; this includes comparing both static and dynamic
measures of uptake. Secondly, to compare these quantitative measures against clinical
measures of inflammation obtained from inflammatory cell counts in bronchoalveolar
lavage fluid (BALf) and plasma biomarkers of inflammation. Finally, to investigate




The study aimed to recruit 12 pulmonary sarcoidosis patients with clinically active
disease who were eligible for an endobronchial ultrasound (EBUS) procedure with
high volume BAL. A further 12 healthy volunteers were age and sex matched to pa-
tients; they had no smoking history and were free of any confounding inflammatory
disorders; sarcoidosis patients had no history of smoking. Sarcoidosis patients were
eligible provided they had confirmed pulmonary sarcoidosis determined by the inter-
stitial lung disease (ILD) multidisciplinary team (MDT), they had no known other pul-
monary disease (determined by a recent previous chest CT) or chronic inflammatory
disorders. Review of the previous CT scan by the ILD specialist minimised differences
in radiologic appearance of sarcoidosis patients. The study consisted of two visits and
a follow-up telephone call: the screening visit (V1) included the baseline clinical assess-
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ments, the imaging visit (V2) was completed within 6 weeks and included a dynamic
18F-FDG PET scan and cine CT (see figure 6.1).
The study received a favourable ethics opinion and all participants provided written
informed consent in-line with the Declaration of Helsinki.
6.4.2 PET/CT acquisition protocol
The protocol was as described in chapter 3, a brief description follows highlighting the
key differences. Subjects underwent a cine-CT followed by a dynamic 18F-FDG-PET
scan. All imaging was performed on the GE 690 PET/CT scanner at Addenbrookes’
hospital. Cine-CT was performed with the subjects breathing normally, the FOV was
centred on the lungs covering bases to apices, where possible. The Varian respiratory
monitoring system was used [199]: a small reflective block was securely placed on the
chest at the observed point of maximum displacement, an infra-red camera positioned
with full view of the scanner monitored the movement of the block to produce a
respiratory trace. The respiratory trace was observed until the breathing period was
stable and used to inform the cine-CT acquisition parameters (see table 6.1). Longer
respiratory periods required lower tube current, longer cine duration and rotation
time. An example of the respiratory trace is shown in figure 6.2; each trace was divided
into 10 phases. Cine-CT images consisted of 10 different phases of the respiratory
cycle matching the axial field of view of the PET scanner. Following the cine-CT, an
administered activity of approximately 200MBq was given. Dynamic 18F-FDG-PET
scans were binned into 27 frames of durations 10s⇥ 12, 60s⇥ 3, 120s⇥ 5, 300s⇥ 5 and
600s⇥ 2; at approximately 50 mins, a single venous blood sample was taken from the
contralateral arm.
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Table 6.1: Acquisition parameters for CineCT scans of the lungs. Parameters which are subject
specific were based on the respiratory period of the subject.
Parameter Value
Tube voltage (kVp) 120
Tube current (mA) 10 to 20 (subject specific)
Rotation (s) 0.5 to 0.8 (subject specific)
Cine duration (s) 2.5 to 9.6 (subject specific)
Reconstruction Body filter
Slice thickness (mm) 2.5
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Figure 6.1: VERIFY study flow diagram.
⇤ Twelve evaluable patients and matched controls were required before study completion; evaluable
requires both analysable image data and clinical data.
⇤⇤ CT refers to cine-CT.
Part B refers to additional part of study not discussed in this work.
BAL = bronchoalveolar lavage, BMI = body mass index, BP = blood pressure, Ox = oximetry, PFTs = pulmonary
function tests, EBUS = endobronchial ultrasound
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Figure 6.2: Example of the respiratory trace used to gate the Cine-CT acquired using the
Varian real-time position management software [199].
The respiratory cycle was divided into 10 phases and a CT image was reconstructed at each of these
points on the trace.
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6.4.3 Bronchoscopy and BAL
As part of the normal standard of care patients undergo a bronchoscopy procedure
including an EBUS. BAL is performed to obtain a differential cell count from within
the lung. To ensure a sufficient cell count, a narrower scope than standard practice
was used to perform a high volume BAL. Three sequential 50ml volumes of sterile
normal saline were instilled through the bronchoscope. BALf was obtained by gentle
aspiration and samples pooled, return volume was typically 80-100mL, the samples
were gauze filtered and kept on ice for processing. Cell counts and cell differentials
were performed independently by two experienced histopathologists.
6.4.4 Image Analysis - Cine CT and PET
The image analysis pipeline is described in chapter 3. However, processing of the
cine-CT is described here.
Cine-CT images consisted of 10 different phases of the respiratory cycle; these were
combined into a single CT representing the average position of the lung. The atten-
uation correction was performed using the averaged cine-CT during the PET image
reconstruction. To investigate the effect of respiration on quantitative 18F-FDG, indi-
vidual phases in the cine-CT scan were selected and PET images reconstructed using
these for attenuation correction. The phases nearest to end expiration and inspiration
were chosen as these are likely to represent the largest changes in density and motion.
Figure 6.3 shows an example of reconstructed CT images at inspiration and expiration
phases. Consistent with the previous chapters, the SUV reported is the mean SUV; in
this study it was calculated from the final 25 mins of the scan. All subsequent stages
of quantitative PET image analysis are identical to that described in chapter 3. To clar-
ify, the analysis pipeline was identical to that used in chapter 5 and chapter 4 (except
section 4.5.5 which used an alternative pipeline).
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Figure 6.3: Example of CT scans of a sarcoidosis subject from two phases of respiration.
(a) CT acquired near end expiration.
(b) CT acquired near end inspiration.
Cine-CT scans provide images from multiple time points, in (a) the nearest point to end expiration is
shown, (b) is the point nearest end inspiration.
6.5 results
6.5.1 Demographics
Eleven patients were recruited into the study; seven patients completed the study at
the time of writing, the mean age was 46± 8.8 yrs old and with a nearly equal male
and female split (57% male). A total of 4 were withdrawn from the study; either as
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they had another condition (n=2), withdrew voluntarily (n=1) or were ineligible for
another reason (n=1). The mean age of the healthy controls was 45± 8.5 yrs old (with
57% male). The median time between V1 and V2 was 25 days for the sarcoidosis
patients and 22 days for the controls. The demographics and clinical measurements
are summarised in table 6.2. There was no statistical difference in FEV
1
, age or gen-
der between patients and controls. There were no difference between systemic blood
markers of inflammation between sarcoidosis and controls.
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Table 6.2: Demographics and clinical measures of the sarcoidosis patients and controls.
Sarcoidosis (n = 7) Controls (n =7)
Gender (%male) 57 57
Age (years) 46± 9 45± 9
FEV
1
(L) 2.94± 0.47 2.30± 0.6
Fibrinogen (g/L) 2.75± 1.48 2.62± 0.8
WCC (⇥109 /L) 6.44± 2.55 5.2± 1.41
Neutrophils (⇥109 /L) 4.76± 2.02 3.23± 1.50
Lymphocytes (⇥109 /L) 1.02± 0.6 1.94± 0.9
ACE (⇥109 /L) 80.4± 27 NA
FEV
1
= Forced expiratory volume in 1 second, ACE = angiotensin converting enzyme,
WCC = white cell count.
6.5.2 Influence of respiratory motion on 18F-FDG endpoints in Sarcoidosis patients
The volume change between inspiration and expiration was estimated as 4.1± 0.5%,
with a maximal displacement of the diaphragm of 13.2± 1.2mm. The change in frac-
tional air volume between inspiration and expiration was 1.4±0.3% . 18F-FDG imaging
outcomes were estimated using the dynamic PET scans with CT-AC map generated
from the inspiration and expiration CT scans. Table 6.3 summarises the percentage
change in imaging outcomes between the inspiration and expiration CT derived PET
values. Further, the maximum percentage differences in the 18F-FDG imaging out-
comes for either expiration or inspiration compared to the time-averaged CT scans
are reported. The changes were substantial for imaging outcomes but overall SUV
changed the least between inspiration and expiration. With the dynamic measures of
18F-FDG uptake, K
ip
was least affected but still had a maximum change of 24%. The
changes in outcomes between the inspiration CT and expiration CT were greater than
either compared to the time averaged CT.
6.5.3 Comparison of 18F-FDG-PET outcomes in sarcoidosis and controls
Pulmonary inflammation was assessed by static and dynamic 18F-FDG imaging end-
points in the whole lung, the results are summarised in table 6.4. The patients and
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⇤ shows the maximum % difference in 18F-FDG PET outcomes between
expiration and inspiration.
⇤⇤ shows the maximum % change between either inspiration or expira-
tion and the time-averaged cine-CT.
exp = Expiration, insp = Inspiration, V
b
= fractional blood volume.
controls exhibited similar values for fractional air and blood volumes (respectively;
p = 0.21 and p = 0.56) hence, the fractional tissue volume in the lung must also be
similar between these two groups.





and controls (p = 0.022 and 0.025, respectively). In contrast, there was no difference
in whole lung SUV or K
im
values between patients and controls (p = 0.16 and 0.62,
respectively).
Table 6.4: 18F-FDG-PET whole lung imaging outcomes in sarcoidosis patients and controls.
Imaging outcomes Sarcoidosis (n = 7) Controls (n =7)
SUV 0.60± 0.06 0.52± 0.05
K+
ip
[ml/cm3/min-1] 0.92± 0.7⇤ 0.69± 0.6
V
ss
[ml/cm3] 0.27± 0.09 0.28± 0.07
nK+
i
[ml/cm3/min-1] 3.4± 0.4⇤ 2.4± 0.7
K+
im
[ml/cm3/min-1] 6.5± 2.2 5.8± 2.1
V
b
0.14± 0.06 0.12± 0.03
V
a
0.69± 0.03 0.71± 0.03
⇤ p-value < 0.05
+ units are ⇥10-3
V
a
= fractional air volume, V
b
= fractional blood volume
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Regional differences were found within the lungs (see table 6.5). nK
i
values were
modestly increased in the upper and middle lung of sarcoidosis patients compared
to controls (p = 0.029 and p = 0.023, respectively), further K
ip
was also increased in







in the upper, middle or lower lungs between the patients
and controls. For all 18F-FDG outcomes shown in table 6.5, the healthy control group
had very similar values to the never smoking healthy controls in the previous COPD
study (see chapter 4).
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Table 6.5: Regional lung 18F-FDG-PET endpoints in disease and healthy participants.
Sarcoidosis Heathy controls
Upper Middle Lower Upper Middle Lower
SUV 0 .62 ± 0 .07 0 .60 ± 0 .04 0 .58 ± 0 .09 0 .55 ± 0 .06 0 .51 ± 0 .05 0 .50 ± 0 .08
nK+
i
















0.16± 0.045 0.15± 0.036 0.12± 0.039 0.14± 0.036 0.14± 0.035 0.10± 0.027
+ units are ⇥10-3
⇤ indicates a p-value < 0.05 as compared to healthy controls.
V
b
= Fractional blood volume, V
ss
= steady state partition coefficient of 18F-FDG.
6.5.4 18F-FDG endpoints and inflammatory cell counts
The BAL cell counts and differentials are shown in table 6.6. The largest proportion of
cells in the BALf of the patients were lymphocytes and macrophages, the proportion of
eosinophils was negligible. In one patient there was a high proportion of neutrophils
(22%), for the remaining subjects neutrophils were negligible. The correlation coeffi-
cients between each cell line and whole lung 18F-FDG outcomes were estimated. The
correlation between K
ip
and macrophages was r = 0.76 (p = 0.048); the correlation
between K
im
and macrophages was r = 0.73 which was just under the threshold of
significance (p = 0.063). There was no significant correlations between the other cell
lines and any of the 18F-FDG outcomes.
In two patients, additional BAL samples were taken to assess absolute cell counts;
the results are summarised in table 6.7. Both patients had similar total number of
cells per ml of lavage sample. However, subject 2 had increased macrophages and
neutrophils, decreased lymphocytes but similar levels of respiratory epithelial cells
compared to subject 1. The 18F-FDG uptake in subject 2 exhibited larger values than
subject 1 for all outcomes.
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Table 6.6: BAL cell counts and differentials for patients.
BAL measures Sarcoidosis (n =7)
% Neutrophils 9.2± 5.5
% Macrophages 57.8± 20.8
% Lymphocytes 22± 11.0
% Eosinophils 0.8± 0.8
BAL = Bronchoalveolar lavage
Table 6.7: Absolute BAL cell counts and imaging outcomes in Sarcoidosis patients.
Subject 1 Subject 2
Neutrophils (cells/ml) 0 0.11± 0.05
Macrophages (cells/ml) 10.0± 0.06 22.2± 0.1
Lymphocytes (cells/ml) 15.6± 0.08 8.8± 0.08
Respiratory Epithelial (cells/ml) 8.8± 0.09 6.6± 0.08
Squamous (cells/ml) 0.4± 0.07 0










⇤ All BAL measures are ⇥104
+ units are ⇥10-3
BAL = Bronchoalveolar lavage
6.6 discussion
In this study, dynamic 18F-FDG PET was used, for the first time, in sarcoidosis pa-
tients with clinically active disease to assess lung inflammation. Previous studies have
focussed entirely on static measures such as SUV to assess inflammation. Notably, in
these data, Patlak analysis revealed a difference in 18F-FDG uptake between sarcoido-
sis patients and healthy controls which was not evident in static measures (i.e. the
SUVmean). On the whole, there was not enough evidence to conclude that pulmonary
18F-FDG uptake in sarcoidosis represents total inflammatory burden; however, there
was a high correlation between rate of uptake measured using Patlak analysis and
percentage of macrophages. Additionally, compartmental modelling of the 18F-FDG
tracer was not able to detect a difference in pulmonary uptake in sarcoidosis patients,
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similar to the findings in COPD patients.
Several studies have investigated the potential role of 18F-FDG PET in sarcoidoisis
for clinical management and as a predictive tool [200]. Specifically, there have been
numerous studies which have evaluated 18F-FDG as a marker of disease activity [186,
192, 196, 201]. All of these previous studies have been based on SUVmax as a tool for in-
directly measuring pulmonary inflammation. In this study, there was no difference in
whole lung SUV between healthy controls and sarcoidosis patients. This is consistent
with the previous observation that 18F-FDG uptake calculated using dynamic scans
may be more sensitive to low levels of pulmonary uptake [202] and this appears to be
the case in sarcoidosis. Both normalised and unnormalised Patlak outcomes demon-
strated an increase in whole lung 18F-FDG compared to healthy volunteers. Further,
regional analyses found that the upper and middle lung 18F-FDG uptake also appear
elevated. Importantly, the fractional air and blood volumes did not significantly differ





better reflect underlying FDG metabolism than in conditions such as COPD. In
contrast, 18F-FDG uptake determined from compartmental modelling did not show
elevated activity in the sarcoidosis patients either in the whole or regional lung analy-
ses. This is consistent with the earlier observations in COPD patients (see chapter 4).
Despite its limitations, serum ACE is considered a marker of inflammation in sar-
coidosis patients. Despite high levels of measured ACE, there was no correlation be-
tween serum ACE and 18F-FDG uptake assessed by any method in these patients.
Indeed, peripheral blood markers of inflammation in the patients did not show any
correlation with 18F-FDG-uptake. To obtain a more specific relationship to pulmonary
inflammation, cells from within the lung were assessed using BAL. The BALf analysis
revealed high proportions of lymphocytes and macrophages, consistent with previ-
ously reported values in clinically active sarcoidosis patients [203]. A previous study of
sarcoidosis patients demonstrated higher lymphocytosis and total cell count in BALf
in clinically active compared to asymptomatic patients [203]. In another study, uptake
of 18F-FDG in endotoxin challenged healthy volunteers was found to be elevated in
BALf containing cells compared to BALf without cells [23], indicating that 80% of 18F-
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FDG signal was associated with cells. Further, autoradiography revealed that specific
uptake of [3H]-deoxyglucose was confined to the neutrophils, this is consistent with
other early studies [43, 204, 205]. However, there was only a weak correlation between
concentration of neutrophils and K
ip
(R2 = 0.21). In this study, the proportion of neu-
trophils and eosinophils was low or negligible in most patients but there was modest
evidence of correlation between macrophages and K
ip
suggesting that macrophages
may be responsible for elevated 18F-FDG uptake. However, due to the small sample
size, this should be confirmed in larger subject numbers. On the whole, the current
findings in sarcoidosis patients agree with those earlier observations, as there were no
strong associations with any particular cell type and 18F-FDG outcomes.
In a small subset of patients absolute cell counts were calculated and compared to
18F-FDG uptake to elucidate if a particular cell is driving the underlying 18F-FDG sig-
nal. It is not possible to make any firm conclusions since the number of subjects was
too small (due to recruitment issues). Clearly, upon study completion the analyses of
absolute cell counts may provide further insight into the origin of the 18F-FDG signal.
Respiratory motion leads to anatomical mismatch and density variations between
CT and PET scans; these manifest as inaccuracies in the attenuation correction (AC)
map of the PET scan. One method to limit these errors is to use an averaged CT scan
to more closely match the temporal blurring of the PET lung image [112, 113]. Errors
in AC correction lead to over- or underestimation of the radioactivity concentration;
for dynamic data analyses, these manifest as inaccuracies in the time activity curves




). In a previous study, den-
sity and motion mismatches led to significant errors estimating 18F-FDG outcomes us-
ing simulations and real data from idiopathic pulmonary fibrosis (IPF) patients [114].
In that study, K
ip
was shown to be more accurate and stable than the equivalent com-
partmental modelling outcome. Yet, the errors could still be substantial. The findings
presented here in sarcoidosis patients agree with these earlier observations, although
the maximum differences were slightly smaller (K
ip
: -24.1% compared to -30.8%). It
would be expected that the largest mismatches between PET and CT would occur
with CT scans at either end inspiration or expiration. In these data, the maximum
change was indeed greater between expiration and inspiration compared to the differ-
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ence between the time averaged CT and either inspiration or expiration (e.g. change in
K
ip
: 24% compared to 15%). This shows that time averaging the cine-CT may reduce
the variation in 18F-FDG outcomes due to mismatch compared to using a CT from





when estimated using AC maps from different respiratory phases;
this suggests that estimation of K
ip
may be less prone to errors due to respiratory
motion than other dynamic outcomes. However, it is hoped that future studies will in-
clude protocols designed to mitigate these errors through techniques such as shallow
breathing, gated PET or cine-CT [68] .
Only a relatively small sample size was recruited into this study at the time of writ-
ing due to recruitment delays (subsequently worsened by the coronavirus pandemic);
nevertheless, it was shown that 18F-FDG can be used to non-invasively assess dis-
ease activity in sarcoidosis patients. Autoradiography of the BALf was not performed
therefore those cells with a higher affinity for 18F-FDG could not be identified; how-
ever, other studies have demonstrated that 18F-FDG labels inflammatory cells. The
assumption that the cell proportions in a BALf sample is representative of the whole
lung and this is uniform throughout may also be too simplistic; however BAL is of-
ten taken as the gold standard method in pulmonary inflammation [65]. Pulmonary
sarcoidosis has a varying appearance on chest CT between patients, these difference
could result in different patterns of 18F-FDG uptake. Since recent previous CT scans
were reviewed prior to entry into the study by an ILD specialist, these differences are
likely to be minimal.
6.7 conclusion
In summary, quantitative dynamic 18F-FDG demonstrated increased values compared
to healthy controls. It can only be speculated that this is due to pulmonary inflamma-
tion; indeed, the similarity in fractional air and blood volumes between patient and
control groups is suggestive that the increase is related inflammation, but further data
is required before any firm conclusions are made. Patlak graphical analysis demon-
strated increased uptake of 18F-FDG uptake compared to controls, whereas static and
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compartmental modelling analyses found no difference between the groups. The re-
sults suggest that Patlak analyses may be the most suitable method to detect the low
levels of pulmonary 18F-FDG uptake typically present in clinically active sarcoidosis.
Considerable errors in 18F-FDG uptake can be introduced by mismatches between CT
and PET due to respiratory motion underlining the importance of correction methods.
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C O N C L U S I O N S A N D F U T U R E D I R E C T I O N S
Inflammation is a characteristic feature of several lung diseases and is thought to be
an important factor in their pathogenesis and progression. Existing markers which
are used as indirect measures of lung inflammation such as pulmonary function tests
(PFTs) have a number of limitations, particularly in the research setting. For exam-
ple, PFTs do not relate directly to lung dysfunction and exhibit long intervals before
changes in disease manifest in the measurements. Imaging techniques can fulfil many
of the requirements of an improved biomarker for lung inflammation.
Although other imaging modalities are used to assess diffuse lung disease, PET
imaging techniques are capable of evaluating disease activity and improving our un-
derstanding of the molecular basis of disease. Whilst 18F-FDG is not a specific marker
of inflammation, to date, it is the PET tracer which has formed the foundation of
pulmonary inflammation assessment. There are several quantitative 18F-FDG imaging
outcomes which have been disparately applied as endpoints in studies of pulmonary
inflammation. Notwithstanding the low signal-to-noise ratio of 18F-FDG lung images
and errors introduced by respiratory motion, there has been nascent recognition of a
significant knowledge gap regarding the utility of these outcomes as a research tool
and in understanding their biologic interpretation [30]. This work sought to clarify
these issues, by scrutinising these imaging outcomes in different clinical and experi-
mental conditions with the hope it will improve confidence in PET imaging endpoints.
Of course, these issues are not restricted to 18F-FDG; they will exist to a varying extent
for other PET tracers targeting lung inflammation.
Using retrospective data from two complementary imaging studies, pulmonary 18F-
FDG uptake was investigated in COPD patients, ↵
1
-ATD patients, smokers without
COPD and heathy non-smokers. This was performed in a substantially larger cohort
115
116 conclusions and future directions
than previous 18F-FDG imaging studies of COPD [55]. Indeed, in the literature, there
are no comparably sized studies investigating different 18F-FDG outcomes in relevant
human diseases. The results demonstrate that the contending 18F-FDG outcomes pro-
duce disparate findings which are exacerbated by the presence of varying blood and
air volumes due to emphysema. Nevertheless, normalised rate of 18F-FDG uptake,
nK
i
, derived from Patlak analysis revealed elevated uptake consistent with the patho-
physiological understanding of the disease process. Further, nK
i
demonstrated cor-
relation with fibrinogen; another putative marker of inflammation. Indeed, increased
nKi values were found in a subset of COPD patients with similar pulmonary blood
and air volumes to healthy controls, suggesting that the PET signal was related to
increased pulmonary 18F-FDG metabolism. Further, Patlak analysis was shown to be
more reliable than compartmental modelling; both in terms of repeatability assessed
in longitudinal scans of COPD patients and in reproducibility of analysis performed
by two independent operators. This latter observation is due to the wide range of
parameters that can be chosen during implementation of compartmental modelling,
whereas Patlak analysis is better standardised.
In a further development, PET and CT were used synergistically to evaluate associ-
ations between disease severity and disease activity. Sub-typing based on CT features
has identified clear differences in progression of COPD subtypes [176]. Although no
strong evidence of an association was found, new studies continue to refine the CT
subtypes and may identify treatment responders [177]; 18F-FDG PET may have a role
in assessing efficacy of novel anti-inflammatory therapies.
Finally, in a prospective study, dynamic 18F-FDG PET scans were used to evalu-
ate pulmonary inflammation in sarcoidosis patients and healthy controls. These pa-
tients underwent bronchoscopy and BAL allowing inflammatory cell counts within
the lung to be compared to 18F-FDG uptake. Importantly, there was no difference
in fractional blood and air volumes between the patient and control groups. Despite
small numbers, there was evidence that 18F-FDG uptake was increased in sarcoidosis
using Patlak analysis; this was not apparent using static measures such as SUV, one
can speculate that the increased signal was predominately related to inflammation. In-
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terestingly, there was a significant correlation between the proportion of macrophages
and 18F-FDG uptake assessed with Patlak analysis. However, these initial observa-
tions and the relationship between 18F-FDG and pulmonary inflammation will need
to be confirmed upon study completion. Consistent with previous findings [114], mis-
match in CT and PET lung images had a substantial effect on the quantitative 18F-FDG
imaging outcomes; notably, Patlak outcomes were less influenced than compartmen-
tal modelling. This effect will be less pronounced in solid tissues in the lung such as
malignant lesions, but is important in diffuse lung diseases.
Overall, these data suggest that SUV may be inadequate for studies of diffuse lung
disease, especially when large differences in blood and air volume may be present;
in the COPD study this led to non-physiological findings (i.e. healthy controls had
increased uptake). Further, the SUV was insensitive to differences between disease
and healthy groups when this confounder was not present. Equally, the consistent in-
ability of compartmental modelling outcome, K
im
, to discern differences in 18F-FDG
uptake between disease and control groups suggests that compartmental modelling
may have poor utility in studies of diffuse lung disease. This may be due to the in-
herent noise of PET imaging; Patlak analysis uses linear modelling which mitigate
the issues with parameter estimation in noisy PET lung data better than non-linear
compartmental modelling. However, in this work, the sample sizes were small when
comparing groups with similar pulmonary air and blood volumes, therefore it is pos-
sible that an effect may be observed using compartment modelling with larger sample
sizes. All parameters in this work were estimated using indirect methods - that is,
the images were reconstructed prior to fitting linear and non-linear models. Direct
estimation methods (i.e. parameter estimation from PET emission data prior to recon-
struction) has favourable noise characteristics and this may improve the sensitivity of
both Patlak methods and compartmental modelling [206]. Further, improvements in
PET scanner technology - such as whole body PET scanners - will also lead to im-
proved SNR and better parameter estimation [207].




, were the most valuable and re-
liable measures of pulmonary 18F-FDG uptake in diffuse disease. However, it is now
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known that Patlak outcomes are biased by pulmonary air and blood [66] hence they









are similar or not expected to change such as in the
sarcoidosis patient study (chapter 6) or investigating intra-subject treatment effects,
then one can speculate that Patlak outcomes may provide a measure which better re-




are significantly different in subjects
then differences in Patlak outcomes could be driven by these variables rather than
inflammation per se, hence may not be a suitable biomarker for pulmonary inflamma-
tion but may be useful as a marker of disease activity. Further, the poor signal-to-noise
ratio in pulmonary 18F-FDG images appears to limit the application of compartmental
modelling derived putative biomarkers of pulmonary inflammation. Future studies
which incorporate independent measures of pulmonary blood volume (such as 15O-
CO PET) alongside 18F-FDG would be desirable to provide further insight and instill
confidence.
Given the findings of this work, it it evident that meticulous planning is required
when using 18F-FDG PET to study diffuse lung diseases. It is incumbent on the inves-
tigators to give due consideration to the acquisition and analysis of data from such
studies. As is clear from the preceding discussion, the choice of imaging endpoint
has the potential to lead to different conclusions, hence the chosen endpoint should
be rigorously justified. Indeed, this has implications for the selection of subjects; for
example, thought needs to be given to the heterogeneity of disease within a single
patient group and its implications on the imaging outcome (as shown in chapter 5).
Another related factor will be comparisons between groups with different lung tis-
sue fractions, which could lead to different conclusions depending on the imaging
endpoint (as shown in chapter 4). Methods to mitigate respiratory motion ought be
considered prior to a study of diffuse lung disease to minimise the differences in PET
imaging outcomes between scans (see findings from chapter 6). Further, all steps in
the analysis should be kept consistent throughout and clearly documented as seem-
ingly minor changes can result in bias in imaging endpoints (as shown by the poor
reproducibility of compartmental modelling outcomes).
conclusions and future directions 119
An important limitation when evaluating biomarkers of lung inflammation is the
lack of a gold standard. Indeed, it is difficult to assess the accuracy of one outcome
against another without this comparator. Instead this work has evaluated the reliabil-
ity of the different outcomes against established clinical markers, and through assess-
ment of repeatability, reproducibility and dependence on technical factors. One route
to address this problem is the design and fabrication of more realistic lung phantoms
capable of assessing quantitative 18F-FDG [68]; another related method is through
computerised simulation studies [114].
The lack of specificity could be recognised as a limitation of 18F-FDG. However,
18F-FDG provides a measure of integrated inflammatory response and therefore may
be useful in diseases where a specific inflammatory pathway has yet to be identified.
Nonetheless, the development of more specific PET probes capable of targeting indi-
vidual immune cells or other molecules thought to be important to the disease (such
as cytokines [208]) would be beneficial; for example, in efficacy studies of novel ther-
apeutics. Although there are several tracers on the horizon which have been used to
evaluate pulmonary inflammation, these are at the very early stages of development,
most have not yet been tested in human models of disease [50]. These candidate PET
tracers have shown promise in distinguishing animal models of pulmonary inflamma-
tion. Further studies in humans are needed to investigate whether these encouraging
results translate into humans. Questions regarding clinical validity and utility will
also need to be addressed. Yet by adopting well designed preclinical studies early,
strong evidence of a relationship to meaningful biological features can be identified.
Nonetheless, it is probable that 18F-FDG will remain the most widely utilised tracer in
inflammatory lung diseases; the existing literature is compelling and supports contin-
ued use of 18F-FDG for monitoring inflammation in a variety of diseases.
In summary, there is an existing platform of evidence, built on previous studies,
that suggests 18F-FDG PET is a valuable tool for evaluating lung inflammation in
diffuse lung diseases. In these data, although there was increased pulmonary FDG
metabolism in diseased groups compared to healthy controls ostensibly supporting
its continued use, one can only speculate that this is related primarily to underlying
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inflammation. Importantly, the findings reported here demonstrate that different anal-
ysis methods may produce disparate results. Overall, the results suggest that Patlak
analysis may have the most utility when assessing diffuse lung diseases. However, dif-
ferences in Patlak outcomes should be interpreted judiciously, as they may be driven
by differences in pulmonary blood and air along with inflammation. These findings
underlie the need for careful design, analysis and interpretation of studies using 18F-
FDG PET to assess lung inflammation which may make it challenging to implement
as a widespread tool to accurately assess inflammation.
I believe that PET has a potentially useful role in future proof-of-concept studies and
drug efficacy trials. Yet, further work is needed to improve the catalogue of other PET
tracers available to prospective researchers of diffuse lung disease. It is hoped that
through increasing the number of targeted tracers, improving the noise characteristics
of the estimation methods and multiplexed tracer studies will help improved under-
standing of the pathophysiology of lung disease, phenotype patients and facilitate the
discovery of effective therapies.
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